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ABSTRACT 
Uterine leiomyomas, or fibroids, are benign tumors arising from the smooth muscle lining of 
the uterus, the myometrium. They represent one of the most common neoplasms in women 
with an estimated prevalence ranging from 20% to even as high as 77% during the 
reproductive years. Considering their high prevalence, the molecular mechanisms underlying 
leiomyomagenesis have remained relatively unknown. Decades of work with cytogenetics 
have shown that 40-50% of leiomyomas harbor somatic non-random chromosomal 
aberrations, including translocations between chromosome bands 12q15 and 14q24, 
interstitial deletions in 7q, and trisomy of chromosome 12. Rarely, uterine leiomyomas can 
be associated with a familial hereditary leiomyomatosis and renal cell cancer (HLRCC) 
syndrome. HLRCC is caused by heterozygous germline mutations in fumarate hydratase 
(FH), which encodes the enzyme fumarase of the tricarboxylic acid cycle. The known 
somatic chromosomal aberrations and inherited genetic factors do not, however, explain the 
majority of uterine leiomyomas. Recent advances in next-generation sequencing technology 
have enabled comprehensive genome-wide characterization of somatic mutations in human 
tumors. The aim of this thesis was to elucidate the molecular genetic background of uterine 
leiomyomas with next-generation sequencing.  
 
Exome sequencing of 18 uterine leiomyomas and the respective normal myometrial tissue 
from 17 Finnish (Caucasian) patients led to the identification of recurrent somatic mutations 
in mediator complex subunit 12 (MED12). Verification of the mutations and subsequent 
screening of 207 additional tumors by Sanger sequencing revealed a remarkable 70% 
(159/225) of the tumors harbor MED12 mutations. MED12 encodes a component of the 
Mediator multiprotein complex, which participates in the regulation of global as well as 
gene-specific transcription. All the observed mutations resided in exon 2 or the intron 1- 
exon 2 junction, an evolutionarily conserved region of the gene, suggesting that malfunction 
of the region contributes to tumorigenesis. The mutation spectrum included missense, in-
frame insertion-deletion, and intronic mutations, none of which resulted in a truncated 
protein product. Moreover, complementary deoxyribonucleic acid (cDNA) sequencing of 16 
MED12 mutation-positive leiomyomas confirmed predominant expression of the mutant 
alleles. Mutation-positive leiomyomas tended to be smaller in size compared to mutation-
negative lesions (P=0.015). Unsupervised hierarchical clustering of gene expression data 
from ten uterine leiomyomas (eight MED12 mutation-positive and two MED12 mutation-
negative) and the corresponding normal myometrial tissue indicated that the mutation-
positive tumors form a separate group from all the other samples. In addition, pathway 
enrichment analysis of the eight MED12 mutation-positive tumors and their matched 
myometrial tissue identified three significantly altered pathways: focal adhesion, 
extracellular matrix receptor interaction, and Wnt signaling. High mutation frequency and 
clustering of the mutations into an evolutionarily conserved region of the protein indicate 
that MED12 is likely to be a driver gene. Furthermore, the mutation pattern proposes a role 
for MED12 as a putative oncogene. This is the first time MED12 has been implicated in 
human tumorigenesis. 
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Uterine leiomyomas do not affect all ethnicities equally. To validate the finding in another 
ethnic group and to verify the role of MED12 mutations in leiomyomagenesis, a series of 28 
leiomyomas from 18 Black African or Coloured South African women went through Sanger 
sequencing for MED12 exon 2 mutations. Altogether 50% (14/28) of the tumors displayed a 
mutation. Although South African women tended to carry fewer MED12 mutations than 
Finnish women, the small number of cases makes it difficult to draw definitive conclusions 
from the mutation frequency and clinical correlations in this sample series. All in all, 
MED12 mutations occurred recurrently in uterine leiomyomas of South African women, 
which confirms their role in the growth and development of these lesions regardless of 
ethnicity. 
 
Original identification of MED12 mutations took place in a series of histopathologically 
conventional uterine leiomyomas. To assess the relevance of MED12 mutations for possible 
molecular classification of uterine leiomyomas, 137 tumors representing various relatively 
rare clinical uterine leiomyoma subtypes underwent Sanger sequencing for MED12 exon 2 
mutations. The sample series included 103 histopathological uterine leiomyoma variants (59 
cellular leiomyomas, 26 mitotically active leiomyomas, and 18 leiomyomas with bizarre 
nuclei) and 34 uterine leiomyomas from 14 HLRCC-patients. Both the histopathological 
leiomyoma variants and leiomyomas from HLRCC-patients harbored MED12 mutations 
significantly less frequently than conventional leiomyomas (P<0.001). Mitotically active 
leiomyomas represented the only group of tumors with no significant difference in the 
MED12 mutation frequency from conventional leiomyomas. Overall, the results indicate that 
MED12 mutation positivity is a key characteristic of conventional leiomyomas. Furthermore, 
the majority of uterine leiomyomas from HLRCC-patients displayed biallelic FH 
inactivation, however, none of the MED12 mutation-positive tumors belonged to this group, 
suggesting that MED12 mutations and biallelic FH inactivation may be mutually exclusive.  
 
Thorough analysis of somatic variation in the coding regions of uterine leiomyoma genomes 
included exome sequencing of 27 uterine leiomyomas (12 MED12 mutation-negative and 15 
MED12 mutation-positive) and their corresponding normal myometrial tissue. The study 
aimed at searching for novel driver mutations in MED12 mutation-negative leiomyomas and 
additional contributing mutations in MED12 mutation-positive leiomyomas. Focus was on 
recurrently mutated genes. No such genes, however, were observed in either tumor group. 
The complete lack of other recurrent somatic mutations in the examined sample series 
emphasizes the significance of MED12 mutations for the tumorigenesis of uterine 
leiomyomas. Other types of changes, such as structural rearrangements, intronic variants, 
and epigenetic events undetectable by exome sequencing, probably have an impact to the 
development of MED12 mutation-negative lesions. 
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REVIEW OF THE LITERATURE 
1. Human tumor pathogenesis 
 
Human tumor development and progression is a multistep process, which begins when a cell 
or a small group of cells break away from the normal constraints of cell division and start to 
proliferate uncontrollably. After multiple series of divisions and reproduction of abnormal 
cells, a tumor may form. Tumors can be benign or malignant; they can remain within the 
tissue of origin or have the ability to invade nearby tissues and establish new tumors 
(metastases) throughout the body. 
 
As normal cells gradually transform into cancer cells, they acquire physiological capabilities, 
which enable cancer cells to survive, proliferate, and ultimately disseminate. These hallmark 
capabilities include sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion 
and metastasis (Hanahan and Weinberg, 2000); the last distinguishing a malignant tumor 
from a benign tumor. Two additional hallmark capabilities are emerging: reprogramming of 
cellular energy metabolism and avoiding immune destruction (Hanahan and Weinberg, 
2011). The first involves major deregulation of cellular metabolism to support neoplastic 
proliferation and the second enables cancer cells to evade elimination by immune cells. In 
distinct tumor types, acquisition of hallmark capabilities can occur via various mechanisms 
and in different chronological order during tumor pathogenesis.  
 
Tumors are not solely masses of cancer cells, but rather complicated tissues consisting of 
multiple distinct cell types (Figure 1). The majority of the cellular heterogeneity arises from 
various stromal cells, which create the tumor microenvironment that promotes neoplastic 
transformation, supports tumor growth, and protects the tumor from host immunity  
(Egeblad et al., 2010; Hanahan and Coussens, 2012). Heterotypic signaling within the 
microenvironment changes progressively during the course of tumorigenesis (Quail and 
Joyce, 2013). 
Figure 1. Various cell types of 
the tumor microenvironment. 
Adapted from Cell, 144, Hanahan 
and Weinberg, Hallmarks of 
Cancer: Next Generation, p.662, 
Copyright Elsevier (2011), with 
permission from Elsevier. 
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1.1 Genomic instability 
 
Genomic instability in neoplastic cells generates the genetic and phenotypic diversity that 
drives tumorigenesis and is essential for acquisition of the hallmark capabilities (Hanahan 
and Weinberg, 2011). Rarely, certain genetic or phenotypic changes arise, which give 
selective advantage to a subclone of cells, allowing them to outgrow nearby cells. Multistep 
tumor progression is characterized by a series of clonal cell expansions, each of which is 
triggered by an alteration in the genome of a neoplastic cell (Nowell, 1976; Fearon and 
Vogelstein, 1990). Somatic alterations that confer selective growth advantage to a neoplastic 
cell in which they occur are called ‘driver’ mutations. The majority of somatic changes in 
neoplastic cells are, conversely, ‘passenger’ mutations, biologically neutral alterations, 
which are not subject to selection (Greenman et al., 2007). As tumorigenesis proceeds, cells 
at geographically distinct parts of the tumor may start to display different genomic contents, 
a phenomenon called intratumoral heterogeneity (Yachida et al., 2010; Vogelstein et al., 
2013). 
 
The spontaneous mutation rate in normal human cells is remarkably low, approximately 10
-7
 
per gene during each cell cycle (Araten et al., 2005; Bielas et al., 2006). Several layers of 
highly evolved defense mechanisms protect cell genomes against both exogenous (e.g. 
tobacco, chemicals, and sunlight) and endogenous (hormones or the metabolism of nutrients 
within cells) mutagens, as well as deoxyribonucleic acid (DNA) replication errors. For a 
tumor to develop, neoplastic cells need to overcome these defenses to increase their 
mutability (Negrini et al., 2010). The increased mutability improves the chances of cells to 
gain favourable somatic alterations, which confer them with a selective advantage through 
activation of oncogenes, inactivation of tumor suppressor or stability genes, or disruption of 
epigenetic regulation. 
 
1.1.1 Oncogenes 
 
Proto-oncogenes – non-mutated versions of oncogenes – are normal cellular genes that 
function under tight control in the cell signaling circuitry that promotes cell growth and 
differentiation. The products of proto-oncogenes include, for instance, transcription factors, 
growth factor receptors, apoptosis regulators, and signal transducers. Mutations in proto-
oncogenes render the genes continuously active or active in a situation when they are not 
supposed to be leading to an uncontrolled flow of growth-promoting signals in a cell 
(Bishop, 1991). Activation of an oncogene typically confers a growth advantage or increased 
survival for a cell and enables the cell to become independent of growth signaling.  
 
Oncogenes can be activated by three different mechanisms that affect either protein 
expression or structure: gene amplification, point mutation, or chromosomal rearrangement 
(Croce, 2008). A known proto-oncogene ERBB2 (HER2/neu) is frequently amplified and 
overexpressed in breast carcinomas and is correlated with poor prognosis (Slamon, 1987; 
Press et al., 1997). Elevated gene expression levels can be achieved also through a 
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translocation, which juxtaposes a proto-oncogene under the influence of a strong enhancer, 
as seen in the case of MYC in Burkitt lymphoma (Meyer and Penn, 2008). Translocations 
can, at the same time, create novel chimeric oncogenes with abnormal transforming 
properties. The Philadelphia chromosome, a product of a fusion gene BCR-ABL1, is present 
in 90% of chronic myeloid leukemia patients (Nowell and Hungerford, 1960; Rowley, 
1973). Both RAS and BRAF oncogenes are frequently activated by point mutations in various 
different cancers (Garnett and Marais, 2004; Pylayeva-Gupta et al., 2011). Notably, point 
mutations in proto-oncogenes occur recurrently at the same amino acid positions (Vogelstein 
et al., 2013). For example, the majority of BRAF mutations change a valine (V) residue to 
glutamic acid (E) at codon 600 (previously p.V599E) (Davies et al., 2002). This amino acid 
substitution permanently activates the kinase domain of BRAF, which then phosphorylates 
its downstream targets, resulting in aberrant cell growth (Wan et al., 2004). Mutations in 
proto-oncogenes are dominant in nature; a single somatic mutation in one allele of the gene 
is sufficient to change the behavior of a cell.  
 
1.1.2 Tumor suppressor genes 
 
In order to prosper, neoplastic cells need to also circumvent programs that negatively 
regulate cell proliferation. Tumor suppressor genes encode proteins that are involved in 
many such programs. They prevent inappropriate cell cycle progression and ensure that 
anomalous cells are sentenced to death by apoptosis. Protein products of mutated tumor 
suppressor genes display a loss or reduction in their function, which allows cells to get pass 
the cell cycle checkpoints or to avoid apoptosis resulting in unrestricted replication. A few 
tumor suppressor genes encode proteins that modulate the microenvironment in which the 
cells grow (Kinzler and Vogelstein, 1998). The loss of their function generates an abnormal 
stromal environment that contributes to the neoplastic transformation of cells. 
 
In general, both alleles of a tumor suppressor gene have to be inactivated before a cell gains 
a selective advantage, a phenomenon known as the ‘Knudson’s two-hit hypothesis’ 
(Knudson, 1971; Cavenee et al., 1983). Inactivation of the first allele of a tumor suppressor 
gene can occur by deletions or insertions of various sizes, by point mutations, or by 
epigenetic silencing via promoter methylation (Vogelstein and Kinzler, 2004). Elimination 
of the remaining wild-type allele frequently involves a loss of heterozygosity (LOH) event at 
the gene locus, rather than a second independent mutational or promoter methylation event. 
Occasionally, only one inactivated allele of a tumor suppressor gene provides a growth 
advantage to a cell; a condition called haploinsufficiency, where single allele is insufficient 
for producing a normal phenotype (Santarosa and Ashworth, 2004).  Haploinsufficiency can 
also result from a situation where one mutated allele can disrupt the function of a wild-type 
allele in a dominant-negative manner.  
 
RB1 and TP53 are the two most frequently mutated tumor suppressor genes in neoplastic 
cells. Protein products of the genes function as key regulators of two interconnected 
signaling pathways that are essential for cell cycle progression or induction of senescence 
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and programmed cell death (Vogelstein et al., 2000; Classon and Harlow, 2002). Both 
pathways are defected in a variety of human tumors leading to increased cell proliferation 
and decreased rate of apoptosis. Inactivation of RB1 typically results from deletions or 
nonsense mutations, which disrupt the structure of the protein creating truncated protein 
products that undergo rapid degradation in cells. The loss of RB1 function can also occur, at 
times, through promoter hypermethylation (Sakai et al., 1991; Ohtani-Fujita et al., 1997). 
The majority of mutated TP53 alleles, on the other hand, carry missense mutations (Olivier 
et al., 2010), which only slightly alter the protein product. The mutant protein may, in some 
instances, exert dominant-negative effects over the remaining wild-type allele, but in most 
cases both copies of the tumor suppressor gene are mutated (Olivier et al., 2010; Muller and 
Vousden, 2013). 
 
1.1.3 Stability genes 
 
Stability genes encode proteins that maintain and monitor the integrity of the cell genome. In 
contrast to oncogenes and tumor suppressor genes, stability genes do not directly regulate 
cell proliferation. Mutations in these genes lead to various genomic instabilities, such as 
microsatellites and chromosomal changes, which increase the cell’s overall mutation rate and 
expedite the accumulation of genetic alterations in other genes, such as proto-oncogenes and 
tumor suppressor genes (Friedberg, 2003). As with tumor suppressor genes, both copies of 
stability genes must be typically inactivated through mutations or epigenetic silencing before 
their function is lost. 
 
A large number of stability genes are DNA-repair genes, whose protein products correct 
mistakes made during normal DNA replication or as a result of exposure to mutagens, hence 
keeping DNA-level instability at minimum. For example, mismatch repair genes MLH1 and 
MSH2 are part of an evolutionary conserved pathway, which recognizes and repairs 
erroneous insertions, deletions, and misincorporated bases in the DNA sequence. Defects in 
these genes cause a 100- to 1,000-fold increase in mutation production (Ionov et al., 1993; 
Bhattacharyya et al., 1994). Other stability genes participate in processes, such as mitotic 
recombination, chromosomal segregation, and telomere maintenance, all of which involve 
large amounts of chromosomes. Inactivation of these genes causes chromosomal instability, 
the most common form of genetic instability in human tumors (Michor et al., 2005).  
 
1.1.4 Epigenetic modifications 
 
In addition to genetic alterations, epigenetic aberrations play a role in human tumor 
pathogenesis (Baylin and Jones, 2011; Sandoval and Esteller, 2012). Epigenetics is the study 
of changes in gene expression or phenotype that are heritable during cell division, but do not 
alter the DNA sequence. Mechanisms underlying these changes include, for instance, DNA 
methylation and histone modifications. DNA methylation, which refers to the addition of a 
methyl group to a cytosine (C) or guanine (G) residue, is associated with a number of key 
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biological processes, such as embryonic development, X-chromosome inactivation, and cell 
differentiation. In mammals, DNA methylation occurs mostly at CpG dinucleotides, which 
cluster at the promoter region of genes (CpG islands). Aberrant DNA methylation is a 
characteristic observed in various human malignancies. For example, hypermethylation of 
CpG islands has been implicated in the silencing of numerous tumor suppressor genes (Jones 
and Baylin, 2007; Irizarry et al., 2009). Global hypomethylation frequently accompanies 
hypermethylation of promoter regions in tumors leading to chromosomal instability, possibly 
due to activation of transposable elements (Esteller, 2008). The methylation state of a cell is 
plastic, varying with the cell type, developmental stage, and signals from the 
microenvironment (Pelizzola and Ecker, 2011). Therefore, it is difficult to know which 
epigenetic aberrations are the ones that give selective advantage to the cell. 
 
1.1.5 MicroRNAs 
 
Micro-ribonucleic acid (miRNA) genes encode small non-coding RNAs of approximately 
21-23 nucleotides in length that function as regulators of gene expression. Acting at the post-
transcriptional level, miRNAs typically bind to a targeted messenger RNA (mRNA) and 
prevent protein production by suppressing translation and/or initiating mRNA degradation. 
A large number of miRNA genes localize at chromosomal regions that undergo 
rearrangements, deletions, and amplifications in tumors, supporting the notion that 
dysfunction of miRNAs play a frequent part in human malignancies (Calin et al., 2004). 
MiRNA genes can be upregulated or downregulated in neoplastic cells: oncogenic or tumor-
suppressive, respectively (Volinia et al., 2006). Increased expression of oncogenic miRNAs 
represses target tumor suppressor genes, while the loss of tumor-suppressive miRNAs 
promotes the expression of target oncogenes (Kasinski and Slack, 2011). Upregulation can 
be due to amplifications, deregulation of a transcription factor, or demethylation of CpG 
islands in the promoter region of the miRNA gene. Downregulation, on the other hand, can 
be a result of deletions, epigenetic silencing, or loss of expression of one or more 
transcription factors. For example, members of the let-7 miRNA family directly regulate 
expression of the RAS proto-oncogene in human cells. In lung cancer, deletions or 
underexpression of let-7 results in overexpression of RAS (Johnson et al., 2005). Although 
DNA methylation and histone modifications control the expression of certain miRNAs, 
conversely, miRNAs may also affect the methylation machinery and expression of proteins 
involved in histone modifications (Saito and Jones, 2006; Guil and Esteller, 2009). 
 
1.2 Inherited tumor susceptibility 
 
The vast majority of human tumors arise sporadically over the course of a lifetime and are 
strongly attributed to environmental and lifestyle factors. Inherited tumor susceptibility 
accounts only for approximately 5-10% of all human malignancies (Nagy et al., 2004). 
Hereditary mutations that are passed on from parent to child through the germline increase 
the child’s risk to develop a tumor, but do not directly cause it. Additional somatic mutations 
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are needed for a clinically detectable lesion to emerge. Patients with genetic predisposition to 
tumorigenesis often have multiple primary tumors that appear at an earlier age compared to 
the general population (Knudson, 2002). 
 
Mutations in oncogenes, tumor suppressor and stability genes, as well as miRNAs can occur 
in the germline and result in hereditary tumor predisposition. Mutations are typically subtle 
in nature (point mutations or small insertions and deletions) and inherited in an autosomal 
dominant manner. Although oncogene-activating germline mutations are, in general, 
embryonically lethal, some exceptions exist, such as multiple endocrine neoplasia type 2 
(MEN2) syndrome, which is caused by inherited mutations in the RET proto-oncogene, a 
receptor tyrosine kinase (Donis-Keller et al., 1993; Mulligan et al., 1993). Tumor suppressor 
genes account for the majority of dominantly inherited tumor susceptibility syndromes. 
Many of the genes function in developmental pathways, which frequently lead to phenotypic 
abnormalities when they are not functioning properly (Hodgson, 2008). For instance, 
germline mutations in the APC tumor suppressor gene predispose to familial adenomatous 
polyposis (FAP) (Kinzler et al., 1991). In addition to tumor suppressor genes, inherited 
defects in stability genes are also common, including both autosomal dominant and recessive 
conditions. Hereditary breast and ovarian cancer syndrome is an example of dominant 
inheritance that arises as a result of a germline mutation in either BRCA1 or BRCA2 (Miki et 
al., 1994; Wooster et al., 1995). Ataxia telangiectasia, at the same time, is an autosomal 
recessive syndrome caused by inherited mutations in ATM (Savitsky et al., 1995). Few 
germline mutations in miRNA genes have been observed so far, including one in miR-125a, 
which seems to associate with breast cancer (Li et al., 2009). 
 
Hereditary tumor susceptibility explains only a small fraction of the familial clustering of 
human malignancies. On various occasions, families have more cases of neoplasia than by 
chance, which occur at the average age of onset without a clear pattern of inheritance. A lot 
of this inherited tumor predisposition may be due to a combination of shared lifestyle 
factors, environmental exposures, common low-penetrance, and more rare moderate-
penetrance gene mutations (Cazier and Tomlinson, 2010). 
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2. Next-generation DNA sequencing 
 
Sanger sequencing was the gold standard for nucleic acid sequencing for approximately 25 
years (Sanger et al., 1977). The Human Genome Project (HGP), which established the first 
human baseline reference genome, leaned almost completely on this method (International 
Human Genome Sequencing Consortium, 2004). That project and numerous subsequent 
studies have had a huge impact on the current knowledge of the structure and function of the 
human genome. Since the completion of the HGP, Sanger sequencing has gradually been 
replaced by next-generation sequencing (NGS) technologies, which have significantly 
reduced the cost and increased the output and sensitivity of DNA sequencing. Over a very 
short time period, NGS efforts have discovered novel genes and mechanisms contributing to 
human tumor pathogenesis and considerably improved our understanding of cancer biology. 
 
2.1 Applications of next-generation sequencing 
 
Commercially available NGS technologies vary in several aspects, such as sequencing 
chemistries and signal detection (MacConaill, 2013), but they all follow a similar base 
methodology (Figure 2). Template preparation involves construction of a DNA sequencing 
library; a fragmented genomic DNA population with synthetic adapters ligated to the ends of 
the fragments. The library is subsequently amplified onto a solid surface (a bead or a glass 
slide) to separate the fragments spatially. This enables concurrent sequencing of millions of 
fragments in unison. Sequencing reactions rely on a sequencing-by-synthesis strategy. 
Detection of nucleotide sequencing information can take place through, for instance, pH 
changes or fluorescence. 
 
  
Figure 2. Schematics for 
NGS methodology. Adapted 
by permission from MacMillan 
Publishers Ltd: Journal of 
Investigative Dermatology 
(Grada and Weinbrecht, 2013), 
copyright 2013.  
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Raw sequencing data is a subject to several preprocessing steps, such as the removal of 
adapter sequences and low quality reads, the alignment to the human reference genome, or 
less frequently de novo assembly. The National Center for Biotechnology Information 
(NCBI) maintains and updates the latest version of the human genome, which is available in 
public databases (http://www.ncbi.nlm.nih.gov/genome/guide/human/). To identify somatic 
mutations in the genomes of neoplastic cells, NGS data from both the individual’s germline 
DNA and the tumor DNA is required. Furthermore, various public databases provide a 
growing number of NGS data that assist substantially with the removal of germline 
variation. Instead of whole-genome sequencing, a variety of NGS applications concentrate 
on targeted regions of the genome, ranging from hundreds of genes to the exome. The 
capture of the target DNA fragments from the sequencing library typically involves a 
hybridization reaction between the genomic DNA and a highly specific oligonucleotide 
probe set (Gnirke et al., 2009). 
 
2.1.1 Whole-exome sequencing 
 
The exome consists of all protein-coding regions of the genes (exons). Although the exome 
accounts for only approximately 1% of the human genome, 85% of disease-causing 
mutations are thought to be located in this region (Majewski et al., 2011). During the last 
few years, whole-exome sequencing efforts have made progress in the field of gene 
discovery. For example, identification of frequent BAP1 mutations in metastasizing uveal 
melanomas and ARID1A mutations in ovarian carcinomas have linked these genes, for the 
first time, to these diseases (Harbour et al., 2010; Wiegand et al., 2010). Whole-exome 
sequencing enables robust detection of point mutations, and small insertions and deletions 
with an average of 100- to 150-fold coverage (Garraway and Lander, 2013). Deep coverage 
is important due to the cellular and molecular heterogeneity of most tumors. Advances of 
NGS in research have facilitated the entry of whole-exome sequencing, together with 
targeted gene panels, in clinical practise. In 2011, Ambry Genetics became the first CLIA-
certified (Clinical Laboratory Improvement Amendments) laboratory to offer whole-exome 
sequencing along with medical interpretation for clinical diagnostic purposes.  
 
2.1.2 Whole-genome sequencing 
 
Whole-genome sequencing provides the most comprehensive picture of the genetic variation 
in the genome, including non-coding changes, copy-number alterations, and structural 
rearrangements, with an average of 30- to 60-fold coverage (Garraway and Lander, 2013). 
Since the publication of the first whole cancer genome effort – acute myeloid leukemia – in 
2008 (Ley et al., 2008), the number of whole-genome sequencing studies has continuously 
increased. Sequencing of tumor genomes has provided new insights into various mutational 
mechanisms contributing to tumor development and progression. For example, whole-
genome sequencing of chronic lymphocytic leukemia resulted in the discovery of 
chromothripsis, a phenomenon where a single chromosome or a chromosome arm shatters 
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and reassembles back together in a random order in one single event (Stephens et al., 2011). 
Subsequent studies have indicated that chromothripsis is present in approximately 2-3% of 
all human cancers (Forment et al., 2012; Maher and Wilson, 2012). Advances in NGS 
technologies have launched several large-scale cancer genome projects, such as the 
International Cancer Genome Consortium (ICGC), which aims at generating a thorough 
catalogue of genomic alterations present in 50 clinically and societally important tumor types 
and/or subtypes (International Cancer Genome Consortium et al., 2010). Although the use of 
whole-genome sequencing has started to increase in the clinical setting, several challenges 
have emerged, such as the incomplete depth of coverage for clinical mutation detection in 
the case of 10-19% of inherited disease genes (Dewey et al., 2014).   
 
2.2 Current limitations and challenges 
 
NGS technologies, while revolutionizing the field of tumor biology, have technical 
limitations. A few of the biggest challenges are due to repetitive DNA, which accounts for 
nearly 50% of the human genome (Alkan et al., 2011; Treangen and Salzberg, 2011). 
Regions of repetitive DNA might cause inaccurate sequencing or ambiguities in alignment or 
de novo assembly of short sequence reads. Another major limitation relates to data 
management and storage. Processing and analysing vast amounts of sequencing data can be 
time-consuming and expensive, posing notable bioinformatical challenges. Continuously 
increasing data volumes also seem to outrun the current archival storage capacity despite the 
development of methods that can facilitate electronic data storage, such as reference-based 
compression (Hsi-Yang Fritz et al., 2011). In addition to technical limitations, interpretation 
of NGS data causes its own problems. At the moment, one of the greatest challenges is to 
distinguish driver mutations from passenger mutations in the genome. Most adult tumor 
genomes harbor an average of 1,000-10,000 somatic substitutions, the majority being 
passenger mutations (Stratton, 2011). Various approaches have emerged to identify genes 
with driver mutations (Vogelstein et al., 2013). They rely on characteristics that serve as 
indicators of positive selection, such as mutation frequency, conservation status of the 
mutated residue, and mutation pattern. In clinical practise, ethical issues of privacy, 
confidentiality, and reporting of the NGS results to patients create challenges (Lolkema et 
al., 2013). It is important to decide the extent to which patients are informed of incidental 
genetic findings, such as mutations predisposing to medically actionable conditions not 
related to the disease under study, or variants with uncertain pathogenic and functional 
significance. Unexpected discoveries and data security concern also the field of cancer 
research (Jarvik et al., 2014). 
  
         
       
  
19 
3. Uterine leiomyomas 
 
Uterine leiomyomas (fibroids or myomas) are benign tumors that arise from the cells of the 
myometrium. They are among the most common neoplasms in women with an estimated 
prevalence of 20-40% during the reproductive years, but also percentages as high as 77% 
have been presented (Cramer and Patel, 1990; Wallach and Vlahos, 2004). Leiomyomas are 
classified as subserous, intramural, or submucous depending on their location in relation to 
the layers of the uterus (Figure 3). Their size varies from microscopically small to over       
20 cm in diameter. Leiomyomas can be either solitary or multiple, and their macroscopic 
appearance is typically spherical, circumscribed, and firm (Cramer and Patel, 1990). 
 
Although the majority of leiomyomas are asymptomatic, approximately 25% of women with 
leiomyomas have clinically relevant lesions, which cause significant morbidity and require 
treatment (Baird et al., 2003). The symptoms, which include prolonged or excessive 
menstrual bleeding, pelvic discomfort, and reproductive dysfunction, depend largely on the 
location, size, and number of leiomyomas. Submucous leiomyomas that grow partially or 
entirely in the uterine cavity are likely to cause abnormal bleeding, infertility, and increased 
risk of miscarriage (Garcia and Tureck, 1984; Stewart, 2001; Bukulmez and Doody, 2006; 
Klatsky et al., 2008; Pritts et al., 2009). They can, for instance, prevent the implantation, or 
possibly disrupt fertilization. Pelvic discomfort, on the other hand, may result from a 
massive uterus with multiple or subserosal leiomyomas, which can put pressure on the 
surrounding organs (Gupta et al., 2008). Intramural leiomyomas, which grow within the 
uterine wall, represent the most common leiomyomas. Occasionally, they may expand 
considerably causing abnormal menstrual bleeding or pelvic pressure. Still today, 
symptomatic uterine leiomyomas are the primary indication for hysterectomy throughout the 
world. Approximately 200,000 hysterectomies are performed for leiomyomas in the United 
States per year (Farquhar and Steiner, 2002; Wu et al., 2007). The estimated annual health 
care costs (surgery, hospital admissions, outpatient visits, and medications) are $4.1-9.4 
billion (Cardozo et al., 2012).  
Figure 3. Location of uterine 
leiomyomas. The figure was retrieved 
September 20, 2014, from NICHD 
Web Site (http://www.nichd.nih.gov/ 
health/topics/uterine/conditioninfo/Pag
es/default.aspx).  
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3.1 Histopathology 
 
Microscopically, leiomyoma consists of intersecting bundles of smooth muscle cells 
separated by abundant extracellular matrix (ECM) containing collagen, fibronectin, and 
proteoglycan. Tumor cells are uniform and elongated in shape with scarce mitotic figures. 
Frequently, leiomyoma may undergo degenerative changes, such as oedema or hyaline 
fibrosis. Conventional uterine leiomyomas account for approximately 90% of all 
leiomyomas (Oliva et al., 2014). The remaining tumors consist of leiomyoma variants, 
which represent a group of heterogeneous lesions that mimic malignancy in one or more 
aspects (Table 1). Although associated with malignant features, leiomyoma variants are 
principally clinically benign and managed in the same way as conventional leiomyomas. 
 
Table 1. Examples of histopathological leiomyoma variants and growth patterns according to the WHO 
classification (Oliva et al., 2014). 
 
 
3.2 Epidemiology and risk factors 
 
The current literature on potential risk factors for the development of uterine leiomyomas 
has limitations and requires cautious interpretation. The paucity of epidemiological studies, 
reliability of self-reported diagnoses, and heterogeneity in study designs may complicate the 
characterization of these risk factors (Schwartz et al., 2000). A large proportion of uterine 
leiomyomas are asymptomatic and may not come to medical attention. This may 
occasionally lead to a biased situation where study participants mainly represent 
symptomatic women. 
 
The epidemiology of uterine leiomyomas seems to parallel the changes in estrogen and 
progesterone levels throughout the woman’s reproductive life cycle. Leiomyomas rarely 
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occur, for instance, before puberty. Clinically relevant lesions are most prevalent within the 
reproductive years reaching the peak during perimenopause, and regress after menopause, 
when ovarian hormone concentrations and menstrual cyclicity fade (Marshall et al., 1997; 
Flake et al., 2003). Both early menarche (<10 years old) and nulliparity appear to increase 
the risk to develop leiomyomas, while late menarche (>16 years old), increased parity, and 
longer duration of breastfeeding, decrease the risk, respectively (Ross et al., 1986; Parazzini 
et al., 1996; Marshall et al., 1998; Baird et al., 2003; Terry et al., 2010). One hypothesis 
suggests that lactation reduces the time of exposure to ovarian hormones by decreasing the 
number of menstrual cycles in woman’s reproductive life. Alternatively, early onset of 
menstrual cycles and nulliparity may increase the number of cell divisions that the 
myometrium experiences during the reproductive lifespan, improving the chances of 
mutations to accumulate in myometrial cells (Marshall et al., 1998). The potential effects of 
oral contraceptives or hormone replacement therapy on the growth of uterine leiomyomas 
have presented inconsistent results (Flake et al., 2003). Therefore, no definitive relationship 
between exogenous ovarian hormones and leiomyomas currently exists. 
 
Racial and ethnic differences in the incidence and severity of uterine leiomyomas are 
particularly apparent. For instance, African-American women tend to have a higher 
incidence rate and approximately three times greater risk of developing leiomyomas than 
Caucasian women (Marshall et al., 1997; Baird et al., 2003). The estimated cumulative 
incidence rate of leiomyomas by age 50 is >80% for African-American women, when the 
rate for Caucasian women is approximately 70%. African-Americans have also a younger 
age at diagnosis and at hysterectomy presentation, and at the same time, their leiomyomas 
are larger (heavier uterine weight), more numerous, and more symptomatic than in 
Caucasians (Kjerulff et al., 1996; Huyck et al., 2008). The basis for ethnic disparity in 
uterine leiomyomas remains unknown. One possible reason for the variation in the tumor 
incidence may come from the differences in estrogen metabolism between African-
Americans and Caucasians (Taioli et al., 1996).  
 
Family history and various lifestyle factors may also contribute to the risk of uterine 
leiomyomas. For example, first-degree relatives of women with leiomyomas have an 
approximately 2.5 times higher risk of developing leiomyomas (Vikhlyaeva et al., 1995; 
Schwartz et al., 2000). Obesity, alcohol intake, diabetes, and hypertension seem to also 
increase the leiomyoma risk, while smoking reduces the incidence of leiomyomas in a dose-
dependent manner (Summers et al., 1971; Ross et al., 1986; Shikora et al., 1991; Parazzini et 
al., 1996; Faerstein et al., 2001; Wise et al., 2004; Wise et al., 2005). The influence of diet 
on the presence or growth of leiomyomas is still unclear due to the limited and discrepant 
information available. 
 
3.3 Tumorigenesis 
 
The majority of uterine leiomyomas are monoclonal in origin; in other words, they originate 
from a single myometrial cell (Linder and Gartler, 1965; Townsend et al., 1970; Mashal et 
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al., 1994; Hashimoto et al., 1995). Rarely, polyclonality may also play a part in tumor 
formation (Ozisik et al., 1993). The development of a uterine leiomyoma consists of two 
stages. At first, a normal myometrial cell transforms into a neoplastic myometrial cell, which 
then starts to proliferate in an uncontrolled manner, leading ultimately to a clinically 
apparent tumor. The precise mechanisms underlying leiomyoma pathogenesis are still 
largely unknown. 
 
3.3.1 Initiation 
 
The initiators of uterine leiomyomas remain unidentified, but several hypotheses exist. 
Transformation from a normal to an abnormal myometrial cell likely results from a genetic 
or epigenetic alteration induced by a preceeding condition or injury in the uterus. For 
example, elevated levels of estrogen and progesterone in the myometrium may contribute to 
tumor formation by increasing the overall mitotic rate and expediting the accumulation of 
somatic mutations (Rein, 2000). Alternatively, significantly elevated estrogen receptor levels 
in the myometrium of leiomyomatous uteri compared to normal uteri suggest that women 
with leiomyomas may have an inborn anomaly in their myometrium (Richards and Tiltman, 
1996). Another hypothesis proposes that different types of injury, such as ischemic injury 
associated with increased vasoconstrictive substances that render the myometrium hypoxic at 
the time of menstruation, may play a role in the genesis of leiomyomas (Stewart and Nowak, 
1998).  
 
In 2007, isolation and characterization of a stem/progenitor cell population from the human 
myometrium provided an entirely new angle to study the cellular origins of uterine 
leiomyomas, suggesting that the tumors may arise, instead of normal smooth muscle cells, 
from myometrial stem/progenitor cells (Ono et al., 2007). These cells have the ability to 
proliferate and differentiate into multiple cell types in vitro, such as osteocytes, adipocytes, 
or mature smooth muscle cells. The spontaneous differentiation of stem/progenitor cells into 
smooth muscle cells in vitro occurs only under hypoxic conditions. Therefore, menstruation-
induced hypoxia may potentially function as a driving force, which transforms myometrial 
stem/progenitor cells into more differentiated leiomyoma cells (Zhou et al., 2011). At the 
same time, uterine leiomyomas seem to contain a population of stem/progenitor cells of their 
own, but at a lower percentage than normal myometrium (Chang et al., 2010; Mas et al., 
2012; Ono et al., 2012). One hypothesis suggests that these cells may arise from myometrial 
stem/progenitor cells as a result of a genetic alteration (Ono et al., 2012).   
 
3.3.2 Growth and development 
 
After the initial transformation, several factors seem to participate in regulating the growth 
and development of uterine leiomyomas, including ovarian hormones and growth factors. As 
mentioned previously, leiomyomas are estrogen and progesterone dependent tumors. They 
exhibit higher mitotic activity and higher concentrations of estrogen and progesterone 
receptors (ERs and PRs) than the myometrium, as well as alterations in their estrogen 
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metabolism (Flake et al., 2003). For example, reduced activity of the enzyme 17β-
hydroxysteroid dehydrogenase, which converts estradiol to estrone, and increased levels of 
aromatase, an enzyme that catalyzes the conversion of androgens into estrogens, are 
particularly characteristic for leiomyomas (Pollow et al., 1978; Eiletz et al., 1980; Shozu et 
al., 2004). Low levels of 17β-hydroxysteroid dehydrogenase may contribute to the 
accumulation of estradiol in the tumor cells, which in turn upregulates both ERs and PRs, 
leading to leiomyoma growth (Otubu et al., 1982; Folkerd et al., 1984).  
 
The growth-promoting effects of estrogen and progesterone may occur through growth 
factors, which stimulate leiomyoma growth in autocrine and/or paracrine manner (Hyder and 
Stancel, 1999). Transforming growth factor-β (TGF-β), basic fibroblast growth factor 
(bFGF), insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF), and vascular endothelial growth factor (VEGF) are all examples of 
growth factors associated with uterine leiomyomas; the majority are present in leiomyomas 
with higher concentrations than in normal myometrium (Flake et al., 2003). Elevated levels 
of TGF-β signaling in leiomyomas may both promote mitogenesis and stimulate the 
production of ECM (Lyons and Moses, 1990). An increase in the size of a leiomyoma might 
originate from an increase in the number of tumor cells or from an expansion in the size of 
ECM. Basic FGF promotes angiogenesis and increases the proliferation of smooth muscle 
cells (Stewart and Nowak, 1996). Large amounts of this protein are present in the ECM of 
uterine leiomyomas, potentially contributing to tumor growth (Mangrulkar et al., 1995). 
 
Characteristics such as increased synthesis of ECM components, higher expression of 
hormone receptors, and the presence of myometrial contraction-associated proteins in uterine 
leiomyomas have led to a hypothesis that leiomyoma cells resemble myometrial smooth 
muscle cells of pregnancy (Andersen et al., 1993; Andersen and Barbieri, 1995; Lee et al., 
1998; Cesen-Cummings et al., 2000). On the other hand, transplantation studies in mice have 
indicated that multipotent leiomyoma stem/progenitor cells together with myometrial smooth 
muscle cells are capable of generating leiomyoma-like tissue (Mas et al., 2012; Ono et al., 
2012). Because the stem/progenitor cells express extremely low levels of ERs and PRs, the 
growth of these cells may depend on the presence of ER- and PR-positive myometrial 
smooth muscle cells, which could mediate the ovarian hormone signals in a paracrine 
fashion. 
 
3.4 Diagnosis and treatment 
 
An enlarged or irregularly shaped uterus may indicate the presence of uterine leiomyomas 
during a routine pelvic examination. Various imaging techniques are available for 
confirming the diagnosis, including ultrasonography, saline-infusion sonography, and 
magnetic resonance imaging (MRI) (Parker, 2007). Ultrasonography, or ultrasound, serves 
as a routine imaging tool to differentiate uterine leiomyomas from other pelvic conditions, 
but it may be insufficient for assessing the exact number and position of the lesions 
(Dueholm et al., 2002; Khan et al., 2014). Saline-infusion sonography uses saline to distend 
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the uterine cavity and to obtain more accurate information on the inner lining of the uterus 
and its relation to potential submucous leiomyomas. While more costly, MRI is currently the 
most sensitive technique for the detection and localization of leiomyomas (Dueholm et al., 
2001; Dueholm et al., 2002). MRI can differentiate submucous, intramural, and subserosal 
leiomyomas from each other, as well as identify lesions as small as 5 mm in diameter. 
Primarily, MRI is in use to evaluate suspected malignity or before fertility preserving 
surgery. In addition to these imaging techniques, endometrial biopsy, sampling of the uterine 
mucosal lining for excluding hyperplasia and/or cancer from the diagnosis, takes place 
regularly in uterine leiomyoma diagnostics in Finland. Accurate assessment of the size, 
number, and location of leiomyomas is essential when selecting an optimal treatment for the 
patient. The age and reproductive desires of the individual, the presenting symptoms, and the 
skills of the surgeon also affect the management decisions.  
 
The majority of diagnosed uterine leiomyomas are asymptomatic and managed expectantly. 
That said, various treatment options exist for women with symptomatic lesions, such as 
medical therapy, noninvasive or minimally invasive procedures, and surgery. Medical 
therapy is currently a short-term treatment option serving as a temporary relief of symptoms 
or as a pre-operative measure due to the notable risks with long-term therapy or lack of 
evidence regarding newer medical agents and their risks of long-term use (Khan et al., 
2014). Recommended medical treatments include nonsteroidal anti-inflammatory drugs 
(NSAIDs), tranexamic acid, combined oral contraceptive hormones, the levonorgestrel-
releasing intrauterine system, gonadotrophin-releasing hormone analogs (GnRHa), selective 
estrogen and progesterone receptor modulators, and combination drug therapy. One example 
of progesterone receptor modulators recently subject to clinical trials is ulipristal acetate 
(Esmya), which serves at present as a pre-operative treatment for moderate to severe 
symptoms of uterine leiomyomas in Finland (Donnez et al., 2012a; Donnez et al., 2012b). 
 
Surgical therapy is, even today, the standard method for treating uterine leiomyomas. 
Hysterectomy is the only definitive solution, which eliminates both the symptoms and 
chances of recurrence, while myomectomy (either open or minimally invasive surgery) is an 
option for women who wish to retain the uterus and thereby fertility. The introduction of 
several non- or minimally invasive procedures during the recent years has provided new 
options which not only preserve the uterus, but also reduce the recovery time and morbidity 
in comparison to open surgery (Khan et al., 2014). For example, uterine-artery embolisation 
is an image-guided technique that blocks the arterial blood flow to leiomyomas and causes 
them to shrink (Banu et al., 2007). Currently, embolisation is not recommended if the patient 
wishes to get pregnant early after the procedure (Mara et al., 2008). In the future, better 
understanding of leiomyomagenesis may help to develop preventative treatment strategies 
that will reduce the incidence and morbidity of tumors. 
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4. Genetics of uterine leiomyomas 
 
Although the causes and mechanisms of uterine leiomyoma tumorigenesis remain mostly 
unknown, numerous chromosomal and molecular analyses have provided data that support 
the role of genetic factors in the etiology of these tumors. For example, cytogenetic 
karyotyping has revealed that approximately 40-50% of leiomyomas have non-random, 
tumor-specific chromosome aberrations, including aneuploidy and various structural 
changes, such as translocations, deletions, and inversions (Nibert and Heim, 1990; Rein et 
al., 1991). Furthermore, twin studies, familial clustering, and hereditary syndromes have 
provided strong support for genetic liability for uterine leiomyomas. The genetic background 
of leiomyomas appears to be heterogeneous, suggesting that diverse mechanisms may 
contribute to the growth and development of tumors. The known somatic chromosomal 
abnormalities and inherited genetic factors do not, however, explain the majority of uterine 
leiomyomas. Table 2 provides a summary of the key genetic changes that have been 
associated with leiomyomagenesis prior to this thesis work. 
 
Table 2. Key genetic events likely to contribute to the leiomyoma tumorigenesis reported prior to this 
thesis work. The genetic changes are presented in the order in which they occur in the text. 
 
Chromosome band Alteration type Candidate gene Function 
Somatic alterations 12q15 Translocation HMGA2 Transcription regulation 
 14q23-24 Translocation RAD51B DNA repair 
 
7q22 Deletion CUX1 Transcription regulation 
 
6p21 Translocation HMGA1 Transcription regulation 
 
10q22 Translocation KAT6B Histone modification 
Predisposing factors 1q42 Point mutation FH Enzyme (tricarboxylic acid cycle) 
 
4.1 Chromosomal abnormalities 
 
The presence of chromosomal abnormalities in uterine leiomyomas tends to correlate with 
increased tumor size and the anatomic location of the tumor (Brosens et al., 1998; Rein et 
al., 1998; Hennig et al., 1999). For example, leiomyomas with 12q14-15 rearrangements 
have been shown to be larger in size than leiomyomas with either an apparently normal 
karyotype or with interstitial 7q22 deletions. At the same time, submucous leiomyomas 
display fewer abnormalities than intramural and subserous leiomyomas. In addition to 
conventional leiomyomas, both cellular leiomyomas with a greater mitotic index and 
leiomyomas with bizarre nuclei are more likely to have chromosomal abnormalities (Pandis 
et al., 1991; Meloni et al., 1992). 
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4.1.1 Rearrangements of 12q14-15 
 
The most common chromosomal aberrations in uterine leiomyomas are rearrangements of 
12q14-15, present in approximately 20% of karyotypically abnormal tumors (Meloni et al., 
1992). The majority of these rearrangements consist of a single translocation, 
t(12;14)(q15;q23-24), although other rearrangements involving 12q14-15 do exist 
(Kazmierczak et al., 1995; Wanschura et al., 1997; Kurose et al., 2000; Mine et al., 2001; 
Quade et al., 2003; Velagaleti et al., 2010). In addition to uterine leiomyomas, 
rearrangements of 12q14-15 also occur commonly in a variety of other benign mesenchymal 
tumors, such as angiomyxomas, breast fibroadenomas, endometrial polyps, 
hemangiopericytomas, lipomas, pulmonary chondroid hamartomas, and salivary gland 
adenomas, supporting the importance of this region in tumorigenesis (Sandberg, 2005). 
Mapping of the chromosome 12q breakpoint region in both uterine leiomyomas and other 
benign mesenchymal tumors led to the identification of high mobility group AT-hook 2 
(HMGA2), an evolutionary conserved gene encoding a member of the non-histone 
chromosomal high-mobility group A (HMGA) protein family (Ashar et al., 1995; 
Schoenmakers et al., 1995). HMGA proteins regulate transcription indirectly by inducing 
conformational changes in DNA and thus influencing the access of other DNA-binding 
proteins to the target genes (Fusco and Fedele, 2007). They play a role in diverse cellular 
processes, such as proliferation, differentiation, growth, and apoptosis (Grosschedl et al., 
1994; Reeves, 2001). HMGA2 is generally widely expressed in human tissues during early 
development, whereas the expression reduces entirely or to an almost undetectable level in 
adult tissues, apart from lung and kidney (Rogalla et al., 1996; Gattas et al., 1999; Gross et 
al., 2003).  
 
A significant proportion of the chromosome 12 breakpoints in uterine leiomyomas carrying 
t(12;14)(q15;q23-24) map outside the coding regions of HMGA2, the majority in the 5’ 
region and the minority in the 3’ region of the gene, suggesting dysregulation of HMGA2 
expression (Schoenberg Fejzo et al., 1996; Quade et al., 2003). Indeed, uterine leiomyomas 
with rearrangements of 12q14-15 commonly display HMGA2 overexpression (Gattas et al., 
1999; Klemke et al., 2009). Two mechanisms, the disruption of regulatory elements or the 
placement of an effective promoter/enhancer near the gene, may potentially account for the 
aberrant expression. HMGA2 is also one of the major targets of let-7 miRNAs, which can 
directly inhibit HMGA2 expression by binding to its 3’UTR. Removal of the let-7 binding 
site may provide an additional mechanism to upregulate HMGA2 (Mayr et al., 2007; Peng et 
al., 2008; Klemke et al., 2010; Mehine et al., 2013). The presence of t(12;14)(q15;q23-24), 
high HMGA2 expression levels, and low let-7 expression levels all associate with large 
leiomyoma size (Rein et al., 1998; Wang et al., 2007; Peng et al., 2008). Multiple lines of 
evidence show also a relationship between elevated HMGA2 expression levels and cellular 
transformation, which supports the role for HMGA2 in the regulation of cellular proliferation 
(Sandberg, 2005). 
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Involvement of the region 14q23-24 in rearrangements with 12q14-15 is relatively specific 
for uterine leiomyomas (Heim et al., 1988; Turc-Carel et al., 1988; Meloni et al., 1992). 
RAD51 paralog B (RAD51B), the target gene of the 14q breakpoint region, represents a 
candidate translocation partner for HMGA2 (Ingraham et al., 1999; Schoenmakers et al., 
1999). RAD51B is a member of an evolutionarily conserved protein family which plays an 
essential role in the homologous recombination of double-strand DNA breaks (Thacker, 
2005). Although fusion transcripts involving HMGA2 and RAD51B seem to occur in a small 
percentage of uterine leiomyomas, the key pathological event in leiomyomas with 
t(12;14)(q15;q23-24) remains unknown (Schoenmakers et al., 1999; Takahashi et al., 2001). 
One hypothesis suggests that aberrant expression of transcripts containing the intact HMGA2 
could be the primary molecular mechanism underlying these tumors, instead of fusion 
transcripts (Quade et al., 2003). Of note, HMGA2 overexpression is present also in uterine 
leiomyomas without the 12q14-15 rearrangements, indicating a more general role for 
HMGA2 in leiomyomagenesis (Klemke et al., 2009). 
 
4.1.2 Deletions of 7q 
 
The second most common chromosomal aberration in uterine leiomyomas is an interstitial 
deletion of chromosome 7, del(7)(q22-32), accounting for approximately 17% of 
karyotypically abnormal leiomyomas (Sandberg, 2005). Although apparent in other benign 
mesenchymal tumors, this deletion occurs more frequently in leiomyomas than in any other 
solid tumor. Currently, the minimal deletion region on the long arm of chromosome 7 has 
been narrowed down to an area within 7q22 and the relatively high frequency of LOH in this 
region suggests the existence of a tumor suppressor gene (Zeng et al., 1997; Sell et al., 1998; 
van der Heijden et al., 1998; Saito et al., 2005; Vanharanta et al., 2005). The gene-rich 
nature of the 7q22 region, however, has caused difficulties in defining the precise target 
sequence of the deletion that could promote tumorigenesis in uterine leiomyomas. In spite of 
the identification of numerous positional candidate genes on 7q22, such as CUX1, ORC5L, 
PCOLCE, and ZNHIT1, none have been proven to have a consistent causative role in uterine 
leiomyomas (Ishiai et al., 1997; Zeng et al., 1997; Ligon et al., 2002; Mehine et al., 2013; 
Schoenmakers et al., 2013). One of the candidate tumor suppressor genes, cut-like  
homeobox 1 (CUX1), encodes a member of the homeodomain family of DNA binding 
proteins which functions as a transcription factor in multiple cellular processes, including 
cell proliferation, cell motility/invasiveness, and apoptosis (Hulea and Nepveu, 2012; 
Vadnais et al., 2012). The gene was recently identified as a frequent target of chromosome 7 
deletions in myeloid neoplasms (McNerney et al., 2013; Wong et al., 2014). 
 
The del(7)(q22-32) is present as the sole cytogenetic anomaly in a subset of uterine 
leiomyomas, but occurs also simultaneously with t(12;14)(q15;q23-24) in the tumors (Sait et 
al., 1989). Leiomyomas with the sole deletion are smaller in size than leiomyomas with 
t(12;14) or leiomyomas with both the deletion and t(12;14) (Rein et al., 1998; Hennig et al., 
1999). At the same time, leiomyoma cells with del(7)(q22-32) are frequently lost in tissue 
cultures, while they continue to persist in cultures when t(12;14)(q15;q23-24) is present 
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(Xing et al., 1997). These observations suggest that 7q deletions may represent secondary 
changes in the development of uterine leiomyomas. 
 
4.1.3 Rearrangements of 6p21 
 
Rearrangements of 6p21 are frequent events in various benign mesenchymal tumors, such as 
lipomas, pulmonary chondroid hamartomas, and endometrial polyps (Sandberg, 2005). They 
occur also in uterine leiomyomas, although with a much lower frequency, accounting for 
<5% of karyotypically abnormal tumors. The rearrangements in leiomyomas consist mainly 
of various translocations, occasionally involving 14q23-24, and inversions (Nilbert et al., 
1989; Kiechle-Schwarz et al., 1991; Ozisik et al., 1995; Sornberger et al., 1999). High 
mobility group AT-hook 1 (HMGA1), the gene encoding another member of the HMGA 
protein family, maps to 6p21 and represents the primary target region for these 
rearrangements (Kazmierczak et al., 1996; Dal Cin et al., 1997; Williams et al., 1997; Xiao 
et al., 1997). Breakpoints affecting the HMGA1 locus have been demonstrated, in addition to 
uterine leiomyomas, in pulmonary chondroid hamartomas and hamartomas of the breast. 
Despite the sequence and structural similarity between HMGA1 and HMGA2, the expression 
patterns of these genes seem to differ substantially from each other (Sandberg, 2005). For 
example, overexpression of HMGA1 correlates, in particular, with a malignant phenotype in 
a number of epithelial tumors and leukemia (Cleynen and Van de Ven, 2008). In the case of 
uterine leiomyomas, 6p21 rearrangements appear to also upregulate HMGA1 expression 
(Sornberger et al., 1999; Tallini et al., 2000). The level of upregulation, however, is much 
less strong than that of HMGA2 in leiomyomas with 12q14-15 rearrangements in 
comparison to the myometrium (Nezhad et al., 2010). 
 
4.1.4 Other chromosomal abnormalities 
 
Trisomy 12, another non-random chromosomal aberration affecting chromosome 12, is 
present in approximately 12% of karyotypically abnormal leiomyomas (Nilbert et al., 1990a; 
Vanni et al., 1992). This anomaly may potentially result in the upregulation of HMGA2 
expression, as t(12;14)(q15;q23-24), but this time by increasing the gene dosage. A series of 
other chromosomal aberrations of lower frequency than those above exist in uterine 
leiomyomas, including monosomy 10 and various different rearrangements of chromosomes 
1, 3, 10, 13, and X (Sandberg, 2005). For example, mapping of the 10q breakpoint region 
has identified K(lysine) acetyltransferase 6B (KAT6B), a gene encoding a 
histoneacetyltransferase, as a possible candidate target gene (Moore et al., 2004). Many of 
these aberrations occur simultaneously with other chromosomal changes in leiomyomas, 
suggesting their secondary nature in the tumorigenesis. On the other hand, chromosomal 
abnormalities at several loci in individual tumors are consistent with the multistep process   
of tumor development and progression. 
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4.1.5 Clonality 
 
Cytogenetic analyses of multiple leiomyomas from a single uterus have shown that the 
tumors can harbor different chromosomal abnormalities, suggesting that each tumor may 
develop independently (Ligon and Morton, 2000). Supporting evidence has come from X- 
chromosome inactivation studies, which utilize lyonization as their basis to evaluate the 
clonal origin of tumors. Lyonization is a process in which one of the two X chromosomes in 
all female somatic cells is randomly inactivated early in embryogenesis (Morey and Avner, 
2011). The inactivated X chromosome remains inactive throughout the lifetime of a cell and 
passes on to its descendants. A monoclonal tissue represents an identical pattern of X-
chromosome inactivation, while a polyclonal tissue exhibits a mixture of cells expressing 
two different phenotypes. Analyses of X-chromosome inactivation of the glucose-6-
phosphate dehydrogenase isoenzyme or androgen receptor CAG-repeat polymorphisms have 
indicated that most uterine leiomyomas arise independently from a single myometrial cell; 
individual leiomyomas within the same uterus express exclusively one or the other allele 
(Townsend et al., 1970; Mashal et al., 1994; Hashimoto et al., 1995; Zhang et al., 2006). 
Occasionally, however, observations of a common clonal origin for a subset of physically 
distinct leiomyomas in the uterus have emerged, suggesting that multiple tumors may 
develop from a single primary tumor (Nilbert et al., 1990a; Nilbert et al., 1990b; Canevari et 
al., 2005; Mehine et al., 2013). 
 
4.2 Copy-number alterations and gene expression profiling 
 
After decades of work using standard karyotyping to characterize non-random chromosomal 
aberrations in uterine leiomyomas, a number of studies have introduced methods of 
increasingly higher resolution (microsatellite marker analysis, array comparative genomic 
hybridization (CGH), and single nucleotide polymorphism (SNP) array) to identify novel 
and previously undetectable submicroscopic losses and gains of chromosomal material in the 
tumors. Although various genomic regions with copy-number variation have emerged, 
including gains in chromosomes 9q and 19 and losses in chromosome 22q, these alterations 
seem to be infrequent events in the genomes of uterine leiomyomas (Packenham et al., 1997; 
Levy et al., 2000; Bowden et al., 2009; Meadows et al., 2011). The assessment of LOH, 
another method to detect genomic regions that may harbor critical genes involved in 
leiomyomagenesis, has also revealed little evidence of these gross chromosomal events in 
leiomyomas, with the exception of the regions 7q15-31 and 15q25-26 (van der Heijden et 
al., 1998; Mao et al., 1999; Canevari et al., 2005; Vanharanta et al., 2005; Meadows et al., 
2011). Alternatively, a series of studies have applied gene expression microarrays to identify 
differentially expressed genes and pathways between uterine leiomyomas and normal 
myometrium, which could potentially affect tumorigenesis. The gene expression profiles that 
have been generated have, however, differed substantially from each other. This may result 
from differences in microarray techniques, data analysis methods, and ethnicities of the 
patients, or not taking into account that the leiomyomas under study have distinct genetic 
statuses. Despite the variation in the expression profiles, dozens of genes, such as ADH1, 
         
       
  
30 
EGR1, C-FOS, IGF2, and TGFBR2, involved in retinoid metabolism, growth and 
proliferation, differentiation, and ECM formation have come up in several studies, 
suggesting that these factors may play an important role in the development of leiomyomas 
(Arslan et al., 2005; Vanharanta et al., 2006; Ishikawa et al., 2007; Raimundo et al., 2009; 
Csatlos et al., 2013a; Csatlos et al., 2013b). Future research efforts are vitally important to 
better understand the causes and mechanisms of leiomyomagenesis, which could in turn help 
to develop new strategies for prevention and treatment of the disease. 
 
4.3 Predisposing genetic characteristics 
 
Familial aggregation, research on various ethnic groups, twin studies, and association with 
hereditary syndromes have all provided supportive evidence for genetic predisposition to 
uterine leiomyomas. Recently, a genome-wide association study revealed three chromosomal 
loci (10q24.33, 22q13.1, and 11p15.5) associated with increased susceptibility to uterine 
leiomyomas in Japanese women (Cha et al., 2011). This finding was afterwards examined in 
several ethnicities with contradictory results (Eggert et al., 2012; Wise et al., 2012; Edwards 
et al., 2013). Another recent genome-wide linkage and association study in a cohort of 
women with European ancestry suggested fatty acid synthase (FASN) on chromosome 
17q25.3 to be a novel leiomyoma risk allele in white women (Eggert et al., 2012). This gene 
encodes an enzyme FASN, whose levels were three times higher in leiomyomas compared to 
the corresponding myometrium; the same phenomenon was previously associated with 
various neoplasms and linked to tumor cell survival (Pizer et al., 1996; Pizer et al., 1998; 
Liu et al., 2010). Despite these results, so far the only well-known genetic factors that 
predispose to uterine leiomyomas are germline mutations in fumarate hydratase (FH) 
causing an inherited tumor susceptibility syndrome (Tomlinson et al., 2002). 
 
4.3.1 Hereditary leiomyomatosis and renal cell cancer (HLRCC) 
 
Hereditary leiomyomatosis and renal cell cancer (HLRCC; MIM 150800), also known as 
multiple cutaneous and uterine leiomyomatosis (MCUL), is a rare dominantly inherited 
tumor predisposition syndrome characterized by multiple cutaneous and uterine leiomyomas 
and a high risk of developing renal cell carcinomas (Launonen et al., 2001). Cutaneous 
leiomyomas, the most distinctive feature of HLRCC, originate from arrector pili muscles 
attached to hair follicles. They tend to be numerous (ranging from one to hundreds), localize 
on the trunk and limbs, and cause pain in response to touch or temperature changes 
(Lehtonen, 2011). Occasionally, cutaneous leiomyomas can be overlooked or go unreported 
as a result of their subtle or tolerable nature at the time (Alam et al., 2005; Tolvanen et al., 
2012). Uterine leiomyomas in HLRCC occur as large multiple lesions representing more 
severe symptoms and an earlier age of onset than their sporadic counterparts. In contrast to 
cutaneous and uterine leiomyomas, renal cell carcinomas (mostly papillary type II) are 
present only in a fifth of HLRCC-families worldwide (Launonen et al., 2001; Tomlinson et 
al., 2002; Toro et al., 2003; Vahteristo et al., 2010). They are, however, exceptionally 
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aggressive tumors, which can metastasize in the very early stages, creating a challenge for 
the diagnosis and treatment of these lesions. 
 
Heterozygous germline mutations in FH at chromosome 1q42 underlie HLRCC (Tomlinson 
et al., 2002). The gene encodes the enzyme fumarase, a component of the mitochondrial 
tricarboxylic acid cycle (TCAC) which catalyzes the hydration of fumarate to malate. The 
majority of FH germline mutations are missense (~58%), nonsense (~11%), or frameshift 
mutations (~18%) scattered throughout the gene (Bayley et al., 2008; Lehtonen, 2011). 
Furthermore, HLRCC-associated tumors frequently display biallelic inactivation of FH 
indicating that the gene functions as a tumor suppressor. Loss of the wild-type allele occurs 
mainly through LOH, but occasionally point mutations can serve as second hits (Kiuru et al., 
2001; Launonen et al., 2001). Biallelic inactivation of FH results in elevated levels of 
fumarate and succinate, an intermediate in the TCAC prior to fumarate (Pollard et al., 
2005a). TCAC is part of the aerobic respiration process in the cell’s energy metabolism. The 
most extensively studied hypothesis on the molecular mechanisms of HLRCC tumorigenesis 
is “pseudohypoxia”. The excessive amount of fumarate or succinate in a cell seems to 
aberrantly stabilize HIF1, a key-signaling molecule in the hypoxia pathway, despite the 
presence of oxygen (Isaacs et al., 2005; Pollard et al., 2005b). Activation of the pathway, in 
turn, leads to upregulation of several HIF1 target genes involved in vascularization, 
glycolysis, and glucose transport, processes that can promote tumor growth. Of note, 
biallelic inactivation of FH has been reported in only 1.3% of sporadic leiomyomas (Kiuru et 
al., 2002; Lehtonen et al., 2004; Vaidya et al., 2012). 
 
4.3.2 Other hereditary syndromes associated with uterine leiomyomas  
 
Uterine leiomyomas occur, in addition to HLRCC, in the context of other hereditary 
syndromes, such as tuberous sclerosis (TSC), Birt-Hogg-Dubé (BHD), and Cowden 
syndrome. TSC is a rare, multi-system genetic disease resulting from heterozygous germline 
mutations in the tumor suppressor genes TSC1 and TSC2 (European Chromosome 16 
Tuberous Sclerosis Consortium, 1993; van Slegtenhorst et al., 1997). One of the several 
animal models for TSC, the Eker rat with a germline mutation in one allele of Tsc2, has been 
shown to develop uterine leiomyomas spontaneously at a high frequency (~65%) (Everitt et 
al., 1995; Walker et al., 2003). These tumors are histologically similar to conventional 
human leiomyomas and display loss or reduction of tuberin, the gene product of Tsc2, in 
comparison to normal myometrium (Hunter et al., 2002). As in their human counterparts, 
hormonal factors play an important role in the development of these leiomyomas (Walker, 
2002). The Eker rat acts as an established animal model for uterine leiomyomas. 
Furthermore, spontaneous uterine leiomyomas arise also in German shepherd dogs, a canine 
model for BHD, carrying a germline Bhd mutation (Moe and Lium, 1997; Lingaas et al., 
2003). Of note, the co-occurrence of renal cell carcinomas and uterine leiomyomas in 
HLRCC and both animal models above suggests a possible genetic link between these 
carcinomas and uterine leiomyomas. Cowden syndrome, also known as multiple hamartoma 
syndrome, is caused by germline mutations in the tumor suppressor gene PTEN (Liaw et al., 
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1997). Approximately 50% of women with the syndrome develop uterine leiomyomas, and 
hence the tumors are part of the minor criteria for the syndrome (Hobert and Eng, 2009). 
 
4.3.3 Genetic polymorphisms and ethnic disparity 
 
Since the ethnic disparity in the incidence and biological behavior of uterine leiomyomas 
may potentially result from racial differences in estrogen metabolism, several studies have 
examined the role of gene polymorphisms in estrogen-metabolizing enzymes as prospective 
susceptibility factors for uterine leiomyomas. One of these enzymes is catechol-O-
methyltransferase (COMT), which catalyzes methyl conjugation of the hydroxyl groups of 
catechol estrogens (Zhu and Conney, 1998). The regulation of COMT activity may indirectly 
modulate the biological effects of estrogen. The most studied polymorphism in the gene, a 
valine-to-methionine (M) substitution at codon 158, influences the enzymatic activity of the 
protein; the V/V genotype associates with the highest, and the M/M genotype with the 
lowest, activity (Lachman et al., 1996). African-American women tend to have a higher 
frequency of the V/V genotype and a lower frequency of the M/M genotype, while the 
opposite applies for white women (Al-Hendy and Salama, 2006). The relationship between 
the V158M polymorphism and uterine leiomyoma susceptibility is still, however, unclear; 
results exist both for and against its involvement (Al-Hendy and Salama, 2006; Denschlag et 
al., 2006; Gooden et al., 2007; de Oliveira et al., 2008; Morikawa et al., 2008; Ates et al., 
2013; Shen et al., 2014). In addition to polymorphisms in estrogen-metabolizing enzymes, 
the role of various polymorphisms in other candidate genes, such as ERα, ERβ, PR, 
androgen receptor, and VEGF, for leiomyoma susceptibility have been studied, but thus far 
with contradictory results. 
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AIMS OF THE STUDY 
The aim of this thesis work was to elucidate the molecular genetic characteristics of uterine 
leiomyomas using next-generation seguencing technology. The specific aim was: 
 
 
1.  To identify recurrent mutations in uterine leiomyomas from Finnish patients by 
exome sequencing 
 
The discovery of highly frequent somatic mediator complex subunit 12 (MED12) exon 2 
mutations clarified the subsequent aims of the study, which were: 
 
2.  To validate the finding and determine the frequency of MED12 exon 2 mutations in 
uterine leiomyomas from South African patients 
 
3.  To determine the frequency of MED12 exon 2 mutations in the most common 
histopathological uterine leiomyoma variants and uterine leiomyomas of HLRCC- 
patients 
 
4.  To discover driver mutations in MED12 mutation-negative and additional 
contributing mutations in MED12 mutation-positive uterine leiomyomas by exome 
sequencing 
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MATERIALS AND METHODS 
1. Samples 
 
1.1 Finnish uterine leiomyoma patient samples (I, III, IV)  
 
1.1.1 Fresh frozen tissue samples (I, IV) 
 
Uterine leiomyoma and the respective normal myometrial tissue samples were collected as 
fresh frozen tissue, in collaboration with Dr. Jari Sjöberg, from a cohort of hysterectomy 
patients in Helsinki University Central Hospital (HUCH), Helsinki, Finland in 2002-2004. 
Clinical information was unavailable to the researchers at the time of surgery. Samples 
comprised two categories: specimens from anonymous patients (“M” patients) and 
specimens from patients who signed an informed consent (“MY” patients). Subsequent 
retrieval of clinical data from pathology reports (only “MY” patients) included patient’s age 
at hysterectomy and number of tumors (solitary/multiple). 
 
In Study I, the exome sequencing sample set consisted of 18 unselected uterine leiomyomas 
and their corresponding normal myometrial tissue, including two tumors from the same 
patient: one tumor (M32m1) with a somatic FH mutation, c.715G>A, p.A239T, and LOH as 
a second hit (Vanharanta et al., 2006), and one FH mutation-negative tumor (M32m8). 
Additional validation set comprised 207 unselected leiomyoma specimens resulting in 
altogether 225 uterine leiomyomas from 80 patients; of these, tumor diameter was obtainable 
for 185 lesions (82%) (Table 3). Gene expression data of ten uterine leiomyoma-
myometrium pairs were also available, nine of which were already part of the exome 
sequencing sample set. 
 
Study IV included previously generated exome sequencing data of 17 (two MED12 
mutation-negative and 15 MED12 mutation-positive) uterine leiomyoma-myometrium pairs 
from Study I, analyzed only in the context of MED12, and newly generated data of ten 
MED12 mutation-negative uterine leiomyomas with matched normal myometrial tissue 
samples (Table 3). None of the MED12 mutation-negative uterine leiomyomas displayed a 
mutation in FH. 
 
Table 3. Uterine leiomyoma patients and tumors from HUCH in Studies I and IV. 
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1.1.2 Formalin-fixed paraffin-embedded tissue samples (III) 
 
Through collaboration with Dr. Ralf Bützow, a set of 103 anonymous formalin-fixed 
paraffin-embedded (FFPE) histopathological uterine leiomyoma variant samples was 
available from the Department of Pathology, HUCH, Helsinki, Finland. The set included 59 
cellular leiomyomas (36 highly cellular and 23 cellular), 18 leiomyomas with bizarre nuclei, 
and 26 mitotically active leiomyomas. Additional 69 conventional FFPE leiomyomas served 
as controls. 
 
1.2 South African uterine leiomyoma patient samples (II) 
 
Prof. Zephne van der Spuy and Prof. Ian Tomlinson provided genomic DNA (gDNA) of 28 
fresh frozen uterine leiomyoma and 14 respective normal myometrial tissue samples 
representing 18 patients with African ancestry from the Department of Obstetrics and 
Gynaecology, Faculty of Health Sciences, University of Cape Town/Groote Schuur Hospital, 
Cape Town, South Africa. Clinical information included patient’s age at diagnosis, total 
number of tumors, and tumor size. 
 
1.3 Finnish HLRCC-patient samples (III) 
 
Altogether 34 fresh frozen or FFPE uterine leiomyoma samples and their corresponding 
normal myometrial tissue from 14 Finnish HLRCC-patients were available. The patients 
represented six different HLRCC-families with a known germline FH mutation status  
(Table 4). 
 
Table 4. Finnish HLRCC-families in Study III. 
 
No. of family members Germline FH mutation 
 
Family name in Study III Nucleotide change Amino acid change Reference 
FAM-1 (M) 7 c.671_672delAG  p.E224fs (Launonen et al., 2001) 
FAM-2 (B) 2 c.671_672delAG  p.E224fs (Launonen et al., 2001) 
FAM-3 (C) 2 c.1027C>T p.R343X (Kiuru et al., 2001) 
FAM-4 (D) 1 c.587A>G p.H196R (Lehtonen et al., 2006) 
FAM-5 (E) 1 c.587A>G p.H196R (Lehtonen et al., 2006) 
FAM-9 (N) 1 c.1027C>T p.R343X  - 
 
2. DNA and RNA extraction (I, III, IV) 
 
Extraction of gDNA from fresh frozen tissue followed either a standard non-enzymatic 
method (Lahiri and Nurnberger, 1991) or FastDNA
®
 Kit protocol (MP Biomedicals LLC, 
Solon, OH, USA). Genomic DNA from FFPE tissue was extracted with the NucleoSpin 
FFPE DNA Kit or the NucleoSpin FFPE RNA/DNA Kit (Macherey-Nagel, Düren, 
Germany).
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Extraction and purification of total RNA were in accordance with manufacturers’ 
instructions of TRIzol
®
 Reagent (Invitrogen, Carlsbad, CA, USA) and RNeasy
®
 MinElute™ 
Clean Up Kit (Qiagen GmbH, Hilden, Germany). Conversion of RNA to cDNA complied 
with a standard protocol. 
 
3. Histopathological evaluation (I, III, IV) 
 
Hematoxylin-eosin (HE)-staining of 5 µm FFPE or frozen uterine leiomyoma tissue sections 
complied with standard procedures. Classification of tumors was based on histopathological 
characteristics following WHO criteria (Hendrickson et al., 2003). MED12 mutation status 
was unknown during each histopathological assessment. 
 
In Study I, pathologist Dr. Elina Virolainen reviewed HE-stained frozen tissue sections of all 
the tumors in the exome sequencing and on gene expression arrays to ensure high tumor 
percentage. Another pathologist, Dr. Tom Böhling, evaluated morphology and proliferation 
activity of a set of 93 randomly chosen uterine leiomyomas (67 MED12 mutation-positive 
and 26 MED12 mutation-negative). All the cases represented histopathologically 
conventional leiomyomas. 
 
In Studies III and IV, pathologist Dr. Ralf Bützow reviewed HE-stained FFPE or frozen 
tissue sections from each uterine leiomyoma. Tumors were divided into conventional 
leiomyomas, cellular leiomyomas, mitotically active leiomyomas, or leiomyomas with 
bizarre nuclei (i.e. atypical). The number of mitoses per 10 high-power fields (HPF), the 
degree of cellularity (normal, cellular, and highly cellular), and severity of nuclear atypia  
(0–3) were recorded for each tumor. 
 
4. Exome sequencing and data analysis (I, IV) 
 
4.1 Exome capture and sequencing 
 
Preparation of gDNA libraries of uterine leiomyoma and the respective normal myometrial 
tissue samples followed manufacturer’s protocol of the NEBNext® DNA Sample Prep 
Reagent Set 1 Kit (New England Biolabs Ltd., Hitchin, United Kingdom). Exonic regions of 
the genome were enriched with the Agilent SureSelect Human All Exon Kit (Agilent, Santa 
Clara, CA, USA). Paired-end sequencing of 80-82 base pair (bp) reads was performed with 
Genome Analyzer II (Illumina Inc., San Diego, CA, USA) at the Institute of Molecular 
Medicine Finland (FIMM) Technology Center, Helsinki, Finland. 
 
In Study I, the exome capture kit targeted approximately 38 Mb of coding DNA, whereas in 
Study IV the targeted region was about 50 Mb. 
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4.2 Read mapping and variant calling 
 
Studies I and IV applied different pipelines for raw exome sequencing data (Figure 4). 
Action Study I 
 
Study IV 
 
Reference 
      Raw data FASTQ format 
 
FASTQ format 
  
 
 
 
 
  Quality control FastQC program 
 
FastQC program 
 
http://www.bioinformatics. 
bbsrc.ac.uk/projects/fastqc/ 
 
 
 
 
 Quality trimming NextGENE v.2.1 software 
  
  
 
 
  
  Removal of 3' ends with 
  
In-house script 
  adapter similarity 
  
 
  
    
  Read mapping to the NextGENE v.2.1 software 
 
BWA 
 
(Li and Durbin, 2009) 
reference genome GRCh37/hg19 
 
GRCh37/hg19 
 
 
 
 
 
 
 
 
Removal of duplicate reads 
  
Picard Tools/Markduplicates 
 
http://picard.sourceforge.net 
   
 
 
 
    
 
 
Initial variant calling 
  
Samtools mpileup 
 
(Li et al., 2009) 
   
 
 
 
Local realignment (indels) 
  
Genome Analysis Toolkit 
 
(McKenna et al., 2010) 
   
(GATK) IndelRealigner 
 
 
 
  
 
 
 
Variant calls (SNV + indels)  NextGENE v.2.1 software 
 
GATK UnifiedGenotyper 
 
(McKenna et al., 2010) 
 
BWA: Burrows-Wheeler Aligner; indel: insertion-deletion; SNV: single nucleotide variation 
Figure 4. Processing of raw exome sequencing data in Studies I and IV.  
 
4.3 Analysis of exome sequencing data 
 
Exome sequencing data analysis and visualization were conducted with NextGENE v2.1 
software (Softgenetics, State College, PA, USA) or Rikurator v1.3 Alpha (Katainen, 2013) 
(Table 5). In Study I, the average coverage for each base was 50 reads and 94% of the exonic 
regions covered displayed ≥4 reads. The corresponding numbers in Study IV were 41 reads 
and 90% (≥6 reads). 
         
       
  
38 
Table 5. Detailed information of exome sequencing data analysis in Studies I and IV.  
 
Study I Study IV 
Samples 18 uterine leiomyoma-myometrium pairs 27 uterine leiomyoma-myometrium pairs 
Analysis software NextGENE v2.1 Rikurator v1.3 Alpha 
Analyzed regions Exons, ±3 bp of exon-intron boundaries Exons, ±2 bp of exon-intron boundaries 
Quality filters 
  
   Minimum coverage   
      1) Variation call 4 reads 6 reads 
      2) Mutated allele 20% of the reads 20% of the reads 
   Quality score  - ≥40 (GATK quality calculations) 
Additional filtering 1. respective normal tissue samples 1. respective normal tissue samples 
 
2. rs-coded SNPs (Ensembl59, dbSNP132) 2. rs-coded SNPs (Ensembl59, dbSNP132) 
 
3. 156 in-house control exomes 3. 70 in-house control exomes 
 
4. mutation score ≥6 4. 93 Finnish control genomes  
      (1000 Genomes Project; phase 1 release v2) 
 
5. synonymous coding variants 5. synonymous coding variants 
    6. variants in genes encoding uncharacterized proteins 
  7. variants within 1-10 bp at the end of the reads and 
      present only in the same direction reads 
GATK: Genome Analysis Toolkit 
After exome sequencing data filtering, only tumor-specific alterations remained in the 
analyses. The outcome in Study I was a list of the most frequently mutated genes in the 
examined uterine leiomyomas and in Study IV two lists for both MED12 mutation-negative 
and MED12 mutation-positive leiomyomas: 1) exactly the same variant in at least two 
tumors (common variants) and 2) different variants in the same gene in at least two tumors 
(unique variants). 
 
5. Sanger sequencing 
 
Oligonucleotide primers were designed with Primer3 (Untergasser et al., 2012) with 
GRCh37/hg19 serving as a reference. Polymerase chain reaction (PCR) complied with a 
standard protocol. Purification of PCR products followed the ExoSAP-IT PCR Purification 
Kit (USB Corporation, Cleveland, OH, USA) and sequencing was carried out with the Big 
Dye Terminator v.3.1 Kit (Applied Biosystems, Foster City, CA, USA) on an ABI3730 
Automatic DNA Sequencer (FIMM Technology Centre and DNA sequencing and Genomics 
laboratory, Institute of Biotechnology, Helsinki, Finland) or ABI3100 Capillary Sequence 
Analyzer (Sequencing Core Facility, Haartman institute, Helsinki, Finland) according to the 
manufacturer’s instructions. Sequence graphs were analyzed both with Mutation Surveyor-
software (Softgenetics) and manually. 
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5.1 Verification of exome sequencing variants (I, IV) 
 
Sanger sequencing assessed the presence and somatic status of candidate exome sequencing 
variants. In Study I, this included all variants observed in MED12, the most frequently 
mutated gene among exome-sequenced uterine leiomyomas, and in Study IV, all common 
and unique candidate variants on the generated lists, as well as an unexpected FH mutation 
finding. Somatic status of the variants was verified from the corresponding normal 
myometrial tissue.  
 
5.2 Mutation screening (I-IV) 
 
Validation of MED12 exon 2 mutations in Study I included direct sequencing of 207 
additional fresh frozen uterine leiomyomas (Table 3). To confirm the expression of the 
mutant alleles in the tumors as well as to examine the effect of an intronic variant localized  
8 bp upstream of the intron 1-exon 2 boundary, cDNA sequencing was performed for 19 
MED12 mutation-positive leiomyomas. Furthermore, a series of 30 uterine leiomyomas (20 
MED12 mutation-negative and 10 MED12 mutation-positive) underwent whole gene 
sequencing of MED12 for the identification of possible additional mutations. 
 
In Studies II and III, the frequency of MED12 exon 2 mutations was examined by Sanger 
sequencing. In Study III, two different amounts of DNA (15 and 25 ng) were used to ensure 
accuracy. In Study IV, one tumor with a germline FH mutation (MY31m4) went through 
whole gene sequencing of FH as a part of the assessment of biallelic FH inactivation. 
 
5.3 Loss of heterozygosity analysis (III, IV) 
 
Tumor DNA from patients with a germline FH mutation was sequenced for LOH in Studies 
III and IV. The assessment of LOH on tumor-derived DNA was based on visual observation 
of the sequence chromatograms by comparing the peak heights between the wild-type and 
mutant allele. Scoring of LOH required a recurring and significant reduction in the height of 
the wild-type allele peak when compared to that of the mutant allele. Study III included five 
parallel PCR reactions per FFPE sample to ensure accuracy. In addition, previous LOH data 
were available for 14 out of 34 uterine leiomyomas (Vanharanta et al., 2006; unpublished 
data).
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6. Gene expression profiling (I) 
 
Previously generated transcriptome-wide gene expression data on GeneChip
®
 Human 
Genome U133 Plus 2.0 (Affymetrix, Santa Clara, CA, USA) arrays of 10 uterine 
leiomyoma-myometrium pairs were available for Study I, including eight MED12 mutation-
positive and two mutation-negative leiomyomas. The gene expression data of the mutation-
positive lesions were compared with the data of the mutation-negative lesions as well as 
respective normal myometrial tissue samples in an unsupervised hierarchical clustering using 
a paired t-test. Differentially expressed genes were defined by a fold change difference of 
>1.5. Furthermore, the differentially expressed genes from MED12 mutation-positive uterine 
leiomyomas and their respective normal myometrium underwent pathway enrichment 
analysis. Pathways reached statistical significance with a false discovery rate of <0.05. 
 
7. Statistical and computational analyses 
 
7.1 Significance testing (I-III) 
 
Statistical analyses were performed using R software, version 2.14.0 (www.r-project.org). 
Two-sided Wilcoxon rank sum test with continuity correction was utilized in Study I to 
assess the potential correlation between MED12 mutation status and patient’s age at 
hysterectomy or tumor size. In Study II, Pearson’s chi-squared test was applied to evaluate 
the statistical significance of the difference between the amount of MED12 mutation-positive 
leiomyomas in Finnish and South African patients. Fisher’s exact test revised the same 
difference, when only leiomyomas with a diameter ≥5.5 cm were included in the analysis. 
The chosen size limit represented the average tumor size, when leiomyomas from both 
Finnish and South African patients were taken into account. Study III used solely Fisher’s 
exact test to calculate the statistical significance of differences between MED12 exon 2 
mutation frequencies in various clinical uterine leiomyoma variants and conventional 
leiomyomas. Eight mitotically active leiomyomas with increased cellularity were included in 
both mitotically active and cellular leiomyoma groups. The P-value threshold for statistical 
significance was <0.05. 
 
7.2 In silico predictions (I, IV) 
 
Study I utilized several in silico-software applications to examine the possible consequences 
of intronic variants on splicing and to scrutinize the conservation status of the mutation 
hotspot region near the beginning of MED12 exon 2 (Table 6). In Study IV, multiple types 
of software evaluated the potential functional effects of the identified exome sequencing 
variants (non-synonymous) (Table 6). 
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Table 6. In silico-prediction programs in Studies I and IV. 
 
Software Reference 
Study I   
Splicing prediction ASSP http://www.es.embnet.org/mwang/assp.html 
 
NetGene2 http://www.cbs.dtu.dk/services/NetGene2/ 
Peptide sequence alignment Muscle (Edgar, 2004) 
Intronic sequence alignment Multiz alignments (UCSC) http://genome.ucsc.edu/ 
Secondary structure prediction PSIpred (Bryson et al., 2005) 
Study IV   
Non-synonymous variant prediction Ensembl Variant Effect Predictor (McLaren et al., 2010) 
 SIFT http://sift.jcvi.org/ 
 Polyphen2 http://genetics.bwh.harvard.edu/pph2/ 
 
8. Ethical issues (I-IV) 
 
Studies I, III, and IV were approved by the Ministry of Social Affairs and Health and the 
Ethics Committee for gynaecology and obstetrics, pediatrics and psychiatry of the Hospital 
District of Helsinki and Uusimaa, Finland. Patient samples were obtained either with an 
appropriate informed consent or, in the case of specimens from anonymous patients, with 
authorization from the director of the health care unit. Study II was approved by the local 
Human Research Ethics Committee, Cape Town, South Africa. 
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RESULTS 
1. Highly frequent mediator complex subunit 12 (MED12) mutations in 
uterine leiomyomas (I, II) 
 
1.1 Identification of MED12 exon 2 mutations by exome sequencing (I) 
 
Exome sequencing of 18 uterine leiomyomas from 17 Finnish patients revealed MED12 as the 
most frequently mutated gene among the tumors. Tumor-specific MED12 mutations were 
present in ten out of 18 specimens all locating in exon 2, the majority affecting specifically 
codon 44 (Table 7). None of the other 44 MED12 exons displayed additional variation. 
 
Table 7. Observed MED12 exon 2 mutations in 18 uterine leiomyomas by exome sequencing. The 
nucleotide numbering and amino acid locations follow the transcript sequence: ENST00000374080. 
Mutation type Position Nucleotide change Amino acid change No. of mutations 
Missense X:70339251 c.128A>C  p.Q43P 1 
 
X:70339253 c.130G>A p.G44S 2 
 
X:70339254 c.131G>C p.G44A 2 
 
X:70339254 c.131G>A  p.G44D 2 
 
X:70339254 c.131G>T p.G44V 2 
Deletion X:70339229 c.106_108del3  p.L36del 1 
 
Verification of MED12 exon 2 mutations came from Sanger sequencing of the original 18 
tumors together with 207 additional uterine leiomyomas. Mutation screening discovered a 
remarkable frequency of somatic MED12 mutations in the tumors. Altogether 159 out of 225 
(70.7%) uterine leiomyomas harbored MED12 exon 2 mutations. A notable amount of the 
mutations were located in codon 44 (69.2%; 110/159) including all six possible base pair 
substitutions leading to an amino acid change (Figure 5); a glycine (G)-to-aspartic acid (D) 
change being the most common. Other mutation hotspots consisted of codon 36 (6.9%; 
11/159), codon 43 (1.9%; 3/159), and an intronic site 8 bp upstream of exon 2 (6.3%; 10/159). 
To validate the predicted effect of the intronic variant on the transcript, three available 
leiomyomas underwent cDNA sequencing confirming that the variant added the last six bases 
of intron 1 to the transcript. Various insertion-deletion type alterations, ranging from 3 bp to 
43 bp in length, were observable in 15.7% (25/159) of MED12 mutation-positive 
leiomyomas, all of which were predicted to result in an in-frame transcript. Of note, all 
MED12 mutations were heterozygous, each tumor displaying not more than one mutation. 
Furthermore, multiple tumors from the same patient tended to have distinct MED12 mutation 
statuses. Whole gene sequencing of 20 MED12 mutation-negative and 10 MED12 mutation-
positive uterine leiomyomas did not reveal additional mutations. Overall, a remarkable 60 out 
of 80 patients (75%) had one or more MED12 mutation-positive leiomyomas. 
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Figure 5. MED12 exon 2 mutation spectrum in Study I. 
 
MED12 locates on chromosome Xq13.1 and hence it is subject to random X-chromosome 
inactivation. Analysis of the possible mutant allele expression in the tumors included cDNA 
sequencing of 16 MED12 mutation-positive leiomyomas: 14 tumors with codon 44 mutations, 
one with codon 43, and one with codon 36 mutations. In each case, the mutant allele was 
predominantly present in the cDNA sequence (Figure 6). 
 
 
 c.128A>T, p.Q43P (genomic)              c.128A>T, p.Q43P (cDNA)                                  wild-type 
Figure 6. cDNA sequencing result of a MED12 mutation-positive leiomyoma showing predominance of the 
mutant allele. 
 
1.2 MED12 mutation status correlates with tumor size (I) 
 
The correlation between MED12 exon 2 mutation status and available clinical data was 
examined. MED12 mutation-negative tumors (n=56; median 4 cm) tended to be larger than 
MED12 mutation-positive tumors (n=129; median 3 cm) (P=0.015). No correlation existed 
between the mutation status and patient’s age at hysterectomy (P=0.69). MED12 mutation-
negative tumors (n=66) did not distribute randomly among patients, but rather clustered 
among them (P<10
-6
). Five out of 42 patients (12%) with multiple tumors in the study 
harbored only MED12 mutation-negative tumors, whereas 16 patients (38%) displayed only 
MED12 mutation-positive tumors. The remaining 21 patients (50%) had both MED12 
mutation-positive and -negative tumors, the majority representing mutation-positive lesions.
66/225; 29% 
110/225;49% 
14/225; 6% 
10/225; 5% 
25/225; 11% 
     wild-type 
missense mutation; codon 44 
missense mutation; L36R and Q43P 
intronic variant; E33_D34insPQ 
insertion-deletion mutation (in-frame) 
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1.3 Gene expression profiling (I) 
 
Unsupervised hierarchical clustering of eight MED12 mutation-positive leiomyoma, two 
MED12 mutation-negative leiomyoma, and their respective normal myometrial tissue samples 
indicated that MED12 mutation-positive lesions constitute a separate cluster from the other 
samples. Four of the mutation-positive tumors harbored different codon 44 mutations and four 
tumors displayed the intron 1 mutation. Pathway enrichment analysis of the eight MED12 
mutation-positive leiomyomas and the matched normal myometrium revealed three 
significantly changed pathways: focal adhesion, extracellular matrix receptor interaction, and 
the Wnt signaling pathway. 
 
1.4 MED12 mutations in uterine leiomyomas from South African patients (II) 
 
To validate the finding of MED12 exon 2 mutations in other ethnic groups, the mutation 
frequency was examined in 28 uterine leiomyomas from 18 South African patients 
representing both Black African and Coloured. Half of the tumors displayed MED12 exon 2 
mutations (50%; 14/28), the majority affecting codon 44 (57%; 8/14) (Table 8). Somatic 
status of the mutations was confirmed in cases in which normal myometrium was available 
(71%; 10/14). 
 
Table 8. Identified MED12 exon 2 mutations in uterine leiomyomas from South African women. The 
nucleotide numbering and amino acid locations follow the transcript sequence: ENST00000374080. 
Mutation type Position Nucleotide change Amino acid change No. of mutations out of 28 (%) 
Missense X:70339230 c.107T>G p.L36R 2 (7.1) 
 
X:70339251 c.128A>C p.Q43P 1 (3.6) 
 
X:70339253 c.130G>C p.G44R 1 (3.6) 
 
X:70339253 c.130G>A p.G44S 1 (3.6) 
 
X:70339253 c.130G>T p.G44C 1 (3.6) 
 
X:70339254 c.131G>C p.G44A 1 (3.6) 
 
X:70339254 c.131G>A p.G44D 4 (14.3) 
Splice site X:70339215 c.100-8T>A p.E33_D34insPQ 1 (3.6) 
Deletion X:70339245 c.122_148del27 p.V41_P49 1 (3.6) 
  X:70339272 c.149_163del15 p.A50_D54del 1 (3.6) 
 
The difference between the frequencies of MED12 mutation-positive leiomyomas in Finnish 
and South African women had borderline significance (P=0.045). Because women with 
African ancestry tend to have larger tumors than Caucasian women, the difference was re-
calculated taking into account only uterine leiomyomas with a diameter ≥5.5 cm (Finnish 
n=38; South African n=7). This time, the difference was no longer significant (P=0.69). Of 
note, 45% (17/38) of the larger leiomyomas in Finnish and 57% (4/7) in South African 
women harbored MED12 exon 2 mutations. On the other hand, the difference between the 
frequencies of MED12 mutation-positive leiomyomas in these ethnic groups was statistically 
significant (P=0.011) when tumors with a diameter <5.5 cm (Finnish n=147; South African 
n=7) were considered. Altogether 77% (113/147) and 29% (2/7) of the smaller leiomyomas in 
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Finnish and South African women were MED12 mutation-positive. No statistically significant 
correlation occurred, however, between the MED12 mutation status and tumor size (MED12+ 
n=6, median 9 cm; MED12- n=8; median 5 cm) in South African patients (P=0.40). 
 
2. MED12 mutations in clinical uterine leiomyoma subtypes (III) 
 
MED12 exon 2 mutations were originally identified in a series of histopathologically 
conventional uterine leiomyomas. To examine the frequency of the mutations in rarer clinical 
uterine leiomyoma subtypes, 103 histopathological uterine leiomyoma variants, 34 
leiomyomas from HLRCC-patients, and a control set of 69 conventional leiomyomas went 
through Sanger sequencing. Both the histopathological leiomyoma variants (17%; 18/103; 
P=2.93x10
-8
) and leiomyomas from HLRCC-patients (9%; 3/34; P=5.28x10
-7
) harbored 
significantly fewer MED12 mutations than the conventional leiomyomas (59%; 41/69) 
(Figure 7). Mitotically active leiomyomas were the only variants with no significant 
difference in the MED12 mutation frequency from conventional leiomyomas (38%; 10/26; 
P=0.11). Highly cellular leiomyomas, on the other hand, displayed the lowest frequency of 
MED12 mutations (5%; 2/42; P=1.51x10
-9
). The majority of the observed MED12 exon 2 
mutations located in codon 44 regardless of the clinical leiomyoma subtype in question 
(Figure 7). Novel mutation findings included all the observed 14 insertion-deletion mutations 
and one missense mutation; c.122T>A, p.V41E. 
                    
          Cellular leiomyomas (n=59)           Leiomyomas with bizarre nuclei (n=18)              Mitotically active leiomyomas (n=26) 
          MED12+ 9%; P=2.49x10
-10                                 
MED12+ 17%; P=1.40x10
-3                                                
MED12+
 
38%; P=0.105 
 
    
Leiomyomas from HLRCC-patients (n=34)   Conventional leiomyomas (n=69) 
           MED12+ 9%; P=5.28x10
-7 
                                 MED12+ 59%              
Figure 7. MED12 exon 2 mutation spectrum in clinical uterine leiomyoma variants in Study III. Eight 
mitotically active leiomyomas with elevated levels of cellularity were count in both mitotically active and 
cellular leiomyomas. In terms of mutation spectrum the eight tumors were only part of the mitotically active 
leiomyomas. 
     wild-type 
missense mutation; codon 44 
other missense mutations 
intronic variant; E33_D34insPQ 
insertion-deletion mutation (in-frame) 
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Most leiomyomas from HLRCC-patients (62%; 21/34) showed clear biallelic FH inactivation, 
as a marker of FH driven tumorigenesis, when assessed for LOH. Of note, none of the three 
MED12 mutation-positive leiomyomas in the series (Figure 8) exhibited LOH at the site of 
the FH mutation. 
 
 
        c.131G>A, p.G44D                       c.113_160del48, p.A38_G53del                       c.130G>A, p.G44S 
Figure 8. Sequence chromatograms of three MED12 exon 2 mutation-positive uterine leiomyomas from 
HLRCC-patients. 
 
3. Exomic landscape of uterine leiomyomas (IV) 
 
Exome sequencing data of 15 MED12 mutation-positive and 12 MED12 mutation-negative 
leiomyomas were thoroughly examined to scrutinize somatic variation in uterine leiomyomas; 
the focus was on genes harboring mutations in at least two tumors. No additional contributing 
mutations in MED12 mutation-positive leiomyomas or novel driver mutations in MED12 
mutation-negative leiomyomas were observable. Altogether two unique variants, one in 
MED12 mutation-positive and one in MED12 mutation-negative leiomyoma, were verified: 
NPR2 c.1329G>T, p.L443F and GRIN2B c.1658C>G, p.P553R (Table 9). One MED12 
mutation-positive leiomyoma (MY31m4) unexpectantly displayed a heterozygous germline 
FH mutation, c.1439C>G, p.S480X (Figure 9). Assessment of LOH and other somatic point 
mutations did not show biallelic FH inactivation. 
 
                                                                   Myometrium                                      Leiomyoma 
 
                  MED12                                                                  FH                                                            
 c.100-8T>A, p.E33_D34insPQ                                                    c.1439C>G, p.S480X                               
 
Figure 9. One patient with a MED12 mutation-positive leiomyoma (MY31m4) and a germline FH 
mutation, but no LOH present at the FH mutation site in the tumor. 
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Table 9. Candidate exome sequencing variants in MED12 mutation-positive and MED12 mutation-
negative uterine leiomyomas in Study IV. 
 
Gene Variant In silico prediction Validation status 
MED12 mutation-positive uterine leiomyomas 
   
Common variation 
   TCHHL1 c.1114insC, p.L372fs 
 
False 
WDR6 c.626_627delCT, p.A209fs 
 
False 
Unique variation 
   SCNN1D c.1934C>A, p.S645X 
 
False 
 
c.2024T>A, p.L675H deleterious False 
PBXIP1 c.542A>T, p.Q181L neutral False 
 
c.1294C>A, p.L432M deleterious False 
CA9 c.527C>A, p.A176D neutral False 
 
c.636G>T, p.M212I neutral False 
NPR2 c.1329C>G, p.L443F neutral False 
 
c.1578_1588del11, p.S526fs 
 
True 
MED12 mutation-negative uterine leiomyomas 
 
 Unique variation 
    TTLL4 c.1372C>A, p.Q458K deleterious False 
 
c.2048G>T, p.S683I neutral False 
MUC4 c.4145_4192del48, p.L1382fs 
 
ND 
 
c.11921_11969del48, p.R3974fs ND 
 
c.12496_12542del48, p.A4166fs ND 
PRRC2B c.2905G>T, p.E969X 
 
False 
 
c.5755C>A, p.P1919T deleterious False 
C1RL c.451C>A, p.H151N ND False 
 
c.1141G>A, p.E381K ND False 
GRIN2B c.1658C>G, p.P553R deleterious True 
 
c.3448G>T, p.D1150Y deleterious False 
       
ND; not determined   
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DISCUSSION 
Uterine leiomyomas are one of the most frequent clinically relevant human tumors. That 
said, the molecular genetic background of their tumorigenesis has remained obscure. For 
several decades, classical cytogenetic karyotyping was the primary method to search for 
tumor-specific chromosomal aberrations in leiomyomas. Although various different 
cytogenetic changes emerged, including rearrangements of 12q14-15 and deletions on 
chromosome 7q22, the majority of the tumors remained karyotypically normal (Sandberg, 
2005). Subsequent molecular genetic analyses have concentrated on identifying novel and 
previously undetectable submicroscopical chromosomal events, such as LOH and copy-
number alterations, but suggest that they are relatively rare events in uterine leiomyomas. 
Furthermore, a large number of studies on differential gene expression between uterine 
leiomyomas and normal myometrium have so far led to inconsistent results. Over the past 
decade, NGS technologies have revolutionized the field of tumor genomics by enabling 
comprehensive genome-wide characterization of somatic alterations in a large number of 
tumor specimens. For us, the emergence of these technologies provided an opportunity to 
explicitly detect small tumor-specific alterations (point mutations or insertion-deletions) not 
previously studied in the genomes of uterine leiomyomas, potentially leading to the 
discovery of new candidate driver genes and improving our knowledge of the molecular 
genetic characteristics of these tumors.  
 
1. MED12 in tumorigenesis  
 
1.1 MED12 is the only frequently mutated gene in uterine leiomyomas 
 
Identification of recurrent somatic MED12 mutations by exome sequencing of 18 uterine 
leiomyomas from unselected Finnish (Caucasian) patients and further validation in a series 
of 207 additional leiomyomas revealed that a striking 70% of the tumors display MED12 
mutations. MED12 is a component of the Mediator complex, a large multiprotein assembly 
involved in the gene transcription by RNA polymerase II (Pol II) (Taatjes, 2010). All the 
observed mutations were located in either exon 2 or near the intron 1-exon 2 junction, with 
the majority affecting one single codon: amino acid 44. The mutation spectrum consisted of 
missense, in-frame insertion-deletion, and intronic mutations, none of which truncated the 
protein product (Figure 10). In each case, no more than one mutation was present in the 
tumor. All the mutations were heterozygous, which is consistent with the fact that MED12 is 
an X-chromosomal gene subject to lyonization. Since only one MED12 allele is expressed in 
each tumor cell due to random X-chromosome inactivation, the expression of MED12 
mutant alleles was confirmed by cDNA sequencing in a set of 16 mutation-positive 
leiomyomas. The results indicated that all of the MED12 transcripts derived predominantly 
from the mutant alleles. A minor normal allele peak was apparent in each cDNA sequence 
chromatogram suggesting potential normal tissue contamination. Alternatively, cellular 
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heterogeneity in the tumors may have led to the same outcome. A mostly monoclonal nature 
and a high tumor percentage of uterine leiomyoma samples, however, argue against the 
latter. Whole gene sequencing of 30 leiomyoma samples, both MED12 mutation-positive 
and -negative, did not reveal additional mutations in any other exon of the gene emphasizing 
the specificity of MED12 mutations in these tumors. 
 
Overall, the molecular genetic evidence strongly suggests that MED12 mutations contribute 
to the tumorigenesis of uterine leiomyomas. Furthermore, all the mutations affect an 
evolutionary conserved region of the protein; glycine at codon 44 represents the most 
conserved amino acid among the observed mutation hotspots. This region and especially 
codon 44 seem to be crucial for the normal MED12 function in uterine myometrial cells, 
aberrant function potentially leading to the development and progression of a leiomyoma. 
Currently, one of the major challenges concerning next-generation sequencing data 
interpretation has been the classification of somatic mutations into drivers and passengers. In 
this case, the high frequency of MED12 mutations in uterine leiomyomas and clustering of 
the mutations into a specific, evolutionarily conserved region of the protein indicate that the 
mutations are likely to confer a selective advantage to the cell, consequently establishing 
MED12 as a candidate driver gene. Moreover, the mutation pattern in MED12 suggests that 
the gene functions as an oncogene (Vogelstein et al., 2013). As with oncogenes, the majority 
of MED12 mutations is located recurrently at the same amino acid positions and represents 
missense mutations. This is the first time MED12 has ever been associated with human 
tumor development. 
 
 
 
 
 
 
 
 
 
  
Figure 10. Schematic view of MED12 and the distribution of MED12 hotspot mutations. (Top) The 
number of all the observed MED12 exon 1 and 2 mutations in uterine leiomyomas, including the clinical 
leiomyoma subtypes, from the following studies: Mäkinen et al., 2011a, Mäkinen et al., 2013, Heinonen et al., 
2014, and Kämpjärvi et al., 2014. Missense and splice-site mutations are above and insertion-deletion 
mutations below the amino acid sequence. Grey underlines represent the regions where the insertion-deletion 
mutations are distributed. (Bottom) Overview of MED12 with high-confidence Pfam protein domains in 
yellow, underneath which the protein is divided into domains based on structural and sequence identity (L, 
leucine-rich; LS, leucine-serine-rich; PQL, proline-glutamine-leucine-rich). The leiomyoma-linked mutation 
hotspot and hereditary syndrome-linked germline mutations are marked above the protein. aa; amino acid 
T A C C C T C A G G A C C C C A A A C A G A A G G A G ...497 nt A A A C G C C G C T T T C C T G C C T C A G G A T G A A C T G A C G G C C T T G A A T G T A A A A C A A G G T T T C A A T A A C C A G C C T G C T G T C T C T G G G G A T G A G C A T
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Uterine leiomyomas do not have an equal impact in all ethnicities. Ethnic differences in the 
incidence and severity of uterine leiomyomas between Caucasian women and women of 
African ancestry are particularly evident. Women of African descent are three times more 
likely to develop leiomyomas, have an earlier age at diagnosis and hysterectomy, as well as 
harbor larger, more numerous, and more symptomatic leiomyomas than Caucasians (Kjerulff 
et al., 1996; Marshall et al., 1997; Baird et al., 2003; Huyck et al., 2008). The reasons 
behind ethnic disparity have so far remained unclear. To validate our finding and to verify 
the role of MED12 mutations in tumorigenesis of uterine leiomyomas in an ethnicity other 
than Caucasian, a series of 28 leiomyomas from 18 South African women underwent Sanger 
sequencing for MED12 exon 2 mutations. All in all, 50% of the tumors harbored somatic 
MED12 mutations, codon 44 persisting as the most frequent mutation hotspot. In comparison 
to the Finnish patient series, South African women had a tendency to carry fewer MED12 
mutations. It is noteworthy that MED12 mutation positivity correlated with a smaller tumor 
size in uterine leiomyomas of Finnish origin. At the same time, uterine leiomyomas of South 
African origin tended to be larger in size than their Finnish counterparts. When the 
frequency of MED12 mutation-positive leiomyomas was examined both in tumors with a 
diameter ≥5.5 cm and <5.5 cm in South African women, larger tumors appeared to harbor 
more MED12 mutations than the smaller ones, as opposed to the Finnish sample series.   
 
The uterine leiomyoma sample series from South African patients was relatively small 
(n=28) compared to the Finnish sample series, simultaneously representing two distinct 
subpopulations: Black African and Coloured. The Black Africans account for the majority of 
South Africa’s total population, while the Coloured form a minority group with diverse 
ethnic backgrounds, such as Black, White, Indian, and Chinese. The small number of the 
tumors makes it difficult to draw definitive conclusions, especially regarding the correlation 
between MED12 mutation status and tumor size, and hence more samples are needed for 
further analyses. Despite the scarcity of uterine leiomyomas, our results indicate that women 
with African ancestry also harbor recurrent MED12 mutations in their leiomyomas 
confirming the role of MED12 mutations in tumorigenesis of these lesions regardless of 
ethnicity. Furthermore, MED12 does not seem to explain the ethnic differences between 
Caucasian women and women with African ancestry. 
 
Since the identification of highly frequent MED12 exon 2 mutations in uterine leiomyomas 
of both Finnish and South African origin, several studies have validated and replicated the 
finding in various ethnic groups around the world (Table 10). In each case, the frequent 
occurrence of MED12 mutations in uterine leiomyomas has successfully been confirmed, 
with the reported mutation frequencies varying generally between 50% and 80%. Of note, 
the number of patients and leiomyomas has substantially differed between the studies, which 
may partially explain the variation in the frequencies. Also the differences in tumor 
characteristics, such as size and multiplicity, may have had an impact. For example, our 
recent study indicated that by collecting all feasibly obtainable tumors, even the smallest 
ones, from unselected uterine leiomyoma patients at hysterectomy the MED12 mutation 
frequency could increase even further (Heinonen et al., 2014). Thus, the inclusion of only 
large tumors in these studies may not represent leiomyomas in general. The correlation 
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between MED12 mutation positivity and a smaller tumor size has been confirmed by some 
(Markowski et al., 2012; de Graaff et al., 2013; Heinonen et al., 2014), but not all, 
subsequent studies (Je et al., 2012; Bertsch et al., 2014). Despite a few outliers, MED12 
mutations seem to distribute evenly among the different ethnicities (Table 10). Moreover, the 
majority of uterine leiomyomas in each ethnic group harbor MED12 mutations.  
 
Both the MED12 mutation pattern and spectrum have proved to be similar in uterine 
leiomyomas across all the studies: the clear majority of MED12 mutations consist of 
missense mutations at codon 44, especially the amino acid change G44D. So far, all the 
observed exon 2 mutations have been heterozygous and no more than one mutation has 
occurred per tumor with the exception of one case: a leiomyoma expressing simultaneously 
two codon 44 mutations (c.130G>A, p.G44S and c.131G>A, p.G44D) (Markowski et al., 
2012). 
 
Table 10. Summary of all the studies presenting MED12 exon 2 mutation frequencies for conventional 
uterine leiomyomas. The studies are presented in chronological order. 
Study Ethnicity/nationality (no. of patients) MED12 exon 2 mutation frequency 
Mäkinen et al., 2011a Caucasian/Finnish (80) 159/225 (71%) 
Mäkinen et al., 2011b African/South African (18) 14/28 (50%) 
Markowski et al., 2012 Caucasian/German (50) 47/80 (59%) 
McGuire et al., 2012 Mixed/American (148) 100/148 (68%) 
 White American (120) 79/120 (66%) 
 Black American (23) 18/23 (78%) 
Je et al., 2012 Asian/Korean (67) 35/67 (52%) 
Perot et al., 2012 Caucasian/French (9) 6/9 (67%) 
Ravegnini et al., 2013 Mixed/American (-)  9/13 (69%) 
Markowski et al., 2013 Caucasian/German (-) 10/21 (48%) 
Matsubara et al., 2013 Asian/Japanese (-) 36/45 (80%) 
Mäkinen et al., 2013 Caucasian/Finnish (-) 41/69 (59%) 
de Graaff et al., 2013 Caucasian/Dutch (16) 11/19 (58%) 
Rieker et al., 2013 Caucasian/German (2) 11/12 (92%) 
Schwetye et al., 2014 Mixed/American (28) 15/28 (54%) 
Bertsch et al., 2014 Mixed/American (133) 133/178 (75%) 
 White American (52) 53/74 (72%) 
 Black American (64) 64/81 (79%) 
 Hispanic (13) 13/16 (81%) 
 Asian (4) 4/6 (67%) 
Heinonen et al., 2014 Caucasian/Finnish (28) 138/164 (84%) 
Halder et al., 2014 Mixed/American (135) 92/143 (64%) 
 Black American (68) 45/68 (66%) 
 White American (43) 26/43 (60%) 
 Hispanic (24) 13/24 (54%) 
- ; not clear from the study  
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The original identification of MED12 exon 2 mutations took place in a series of 
histopathologically conventional uterine leiomyomas, which in general account for 
approximately 90% of all leiomyomas (Oliva et al., 2014). In order to evaluate the 
pertinence of MED12 mutations for possible molecular classification of uterine leiomyomas, 
an exceptionally large tumor collection (n=137) of various relatively rare clinical uterine 
leiomyoma subtypes was screened for the mutations. These subtypes included three different 
histopathological uterine leiomyoma variants (cellular leiomyomas, mitotically active 
leiomyomas, and leiomyomas with bizarre nuclei; n=103) as well as uterine leiomyomas 
from HLRCC-patients (n=34). The latter can exhibit the same histopathological 
characteristics as the variants, such as increased cellularity and atypia, but other distinct 
features may also exist, including, for example, orangeophilic nucleoli surrounded by a 
perinuclear halo (Lehtonen, 2011; Sanz-Ortega et al., 2013). All the clinical uterine 
leiomyoma subtypes, except mitotically active leiomyomas, harbored significantly fewer 
MED12 mutations than conventional leiomyomas. The majority of the observed MED12 
mutations represented missense changes at codon 44 (67%; 14/21). Interestingly, while most 
of the studied uterine leiomyomas from HLRCC-patients showed biallelic FH inactivation, a 
well-known attribute of tumors in HLRCC, none of the MED12 mutation-positive tumors 
displayed loss of the remaining FH allele. 
 
Our results suggest that MED12 mutation positivity is a key feature of conventional 
leiomyomas. Cellular leiomyomas and leiomyomas with bizarre nuclei in particular may 
develop primarily through distinct molecular mechanisms. Similar kinds of results regarding 
the rare occurrence of MED12 mutations in these two histopathological leiomyoma variants 
have emerged, with the mutation frequencies ranging between 0-33% (Perot et al., 2012; 
Matsubara et al., 2013; Ravegnini et al., 2013). The number of examined tumors in these 
studies, however, has been extremely small (from 1 to 6). The MED12 mutation frequency in 
mitotically active leiomyomas did not significantly differ from that of conventional 
leiomyomas. This result agrees with the fact that mitotically active leiomyomas actually 
resemble conventional leiomyomas histopathologically, with the exception of increased 
mitotic activity. The elevated number of mitoses may result from hormonal factors, because 
these tumors frequently occur in pregnancy, during the secretory phase of the menstrual 
cycle, and in patients on hormonal therapy (Prayson and Hart, 1992). For example, patients 
using progestin preparations have presented significantly higher mitotic activity in their 
leiomyomas compared to control patients (Tiltman, 1985). None of the uterine leiomyomas 
from HLRCC-patients simultaneously harbored a MED12 mutation and biallelic FH 
inactivation, proposing two different pathogenic pathways. MED12 mutation-positive 
leiomyomas may represent incidental tumors not associated with germline FH mutation. 
 
Recently, somatic MED12 exon 1 mutations were identified at a low frequency (2.5%) in 
uterine leiomyomas (Kämpjärvi et al., 2014). All of the observed mutations represented in-
frame insertion-deletion mutations, which were located at the end of exon 1, affecting the 
same evolutionarily conserved region of the protein as the previously identified exon 2 
mutations (Figure 10). Of note, the MED12 exon 2 mutation-negative uterine leiomyomas 
analyzed in this study came from our three previously described studies: the original exome 
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sequencing study and two subsequent MED12 mutation screening studies in respect to the 
leiomyomas of South African origin as well as clinical uterine leiomyoma subtypes 
(Mäkinen et al., 2011a; Mäkinen et al., 2011b; Mäkinen et al., 2013). Four conventional 
uterine leiomyomas of Finnish origin and one of South African origin, but none of the 
clinical leiomyoma subtypes, harbored a MED12 exon 1 mutation. The low occurrence of 
exon 1 mutations in uterine leiomyomas may explain why these mutations went initially 
unnoticed in the whole MED12 gene sequencing of 20 MED12 mutation-negative 
leiomyomas (Mäkinen et al., 2011a). Interestingly, the study discovered two new cases 
concurrently displaying two different MED12 mutations. Both cases harbored a deletion 
accompanied by a nearby point mutation in exon 1, suggesting that the mutations could have 
resulted from the same mutational event. All in all, the identification of MED12 exon 1 
mutations slightly increases the amount of MED12 mutation-positive leiomyomas and 
emphasizes the significance of these hotspot mutations in the development of uterine 
leiomyomas. 
 
To examine the somatic variation in uterine leiomyoma exomes in more detail, we analyzed 
exome sequencing data of 12 MED12 mutation-negative and 15 MED12 mutation-positive 
uterine leiomyomas. The aim was to search for novel driver mutations in the remaining 
minority of uterine leiomyomas lacking MED12 mutations and additional contributing 
mutations in MED12 mutation-positive leiomyomas, with the main focus on genes mutated 
in at least two different tumors. Of note, each MED12 mutation-negative leiomyoma lacked 
both exon 1 and exon 2 mutations. No recurrently mutated genes were detected in either 
tumor group. The absence of other somatic recurrent point mutations or small insertion-
deletions in MED12 mutation-positive leiomyomas highlights the significance of these 
mutations for the genesis of uterine leiomyomas even further. In the case of MED12 
mutation-negative leiomyomas, the existence of rare driver mutations cannot be excluded 
due to the fairly small number of tumors. Moreover, several different driver genes may 
underlie this tumor group making them difficult to identify from a sample set of this size. 
Also other types of genomic changes, such as structural rearrangements and intronic 
variants, as well as epigenetic events undetectable by exome sequencing, could potentially 
contribute to the development of these lesions. For example, chromosomal rearrangements 
of 12q14-15 giving rise to HMGA2 overexpression have been associated, in particular, with 
MED12 mutation-negative leiomyomas (Markowski et al., 2012; Mehine et al., 2013). 
  
Surprisingly, one sporadic MED12 mutation-positive leiomyoma displayed a truncating 
heterozygous FH mutation, which turned out to be of germline origin. The patient harbored 
five additional tumors each displaying a different MED12 mutation (unpublished data). None 
of the six tumors showed biallelic FH inactivation through LOH or somatic point mutations 
as a second hit in the tumor, favouring the notion that MED12 mutations and biallelic FH 
inactivation are mutually exclusive. Additional support for the hypothesis of mutual 
exclusivity comes from a recent study reporting an HLRCC-patient with 15 uterine 
leiomyomas all lacking MED12 mutations (Heinonen et al., 2014).  
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1.2 Characteristics of MED12 
 
MED12 consists of 45 exons, which span approximately 25 kb of genomic DNA on 
chromosome Xq13 (Philibert et al., 1999; Risheg et al., 2007). The gene encodes a 2177 
amino acid protein divided into four distinct domains on the basis of structural and sequence 
identity: a leucine-rich (L), a leucine-serine-rich (LS), a proline-glutamine-leucine-rich 
(PQL), and an Opa domain (Figure 10). The amino acid sequence is mostly conserved across 
eukaryotic species, specifically in mammals (Kitano et al., 2003). MED12 is ubiquitously 
expressed in multiple human tissues, showing increased expression during fetal development 
(Philibert et al., 1998; Philibert et al., 1999). 
 
MED12 is a component of an evolutionarily conserved multiprotein complex called 
Mediator, which participates in the regulation of global gene transcription in eukaryotic cells 
(Borggrefe and Yue, 2011; Conaway and Conaway, 2011). The complex integrates and 
conveys regulatory information directly to Pol II by acting as a bridge between transcription 
factors and the enzyme, important for both initiation and elongation steps of the transcription 
cycle (Donner et al., 2010; Taatjes, 2010; Takahashi et al., 2011). Mediator consists of four 
structurally distinct modules: three core modules (head, middle, and tail) and a kinase 
module (CDK8 module), which variably associates with the core Mediator (Figure 11). As a 
result, the complex exists in the cell in two different configurations. The core Mediator alone 
stimulates basal transcription (Mittler et al., 2001; Baek et al., 2002), whereas binding of the 
CDK8 module to the core results in decreased gene transcription caused by a structural 
change within the core that prevents interactions with Pol II (Elmlund et al., 2006; Knuesel 
et al., 2009a; Tsai et al., 2013). In addition to its role as a major regulator of global gene 
transcription, Mediator also participates in gene-specific transcription (Borggrefe and Yue, 
2011). Various subunits of the complex serve as targets for different co-regulatory factors at 
different genes, leading to gene-specific physiological effects. Despite the constantly 
increasing amount of studies, the molecular mechanisms by which Mediator regulates gene 
expression are not yet fully understood.  
 
The CDK8 kinase module, a four-subunit complex containing MED12, MED13, CDK8, and 
Cyclin C, can act as a co-repressor or co-activator of gene transcription (Borggrefe et al., 
2002; Samuelsen et al., 2003). Besides binding to the Mediator and sterically blocking its 
interactions with Pol II, the CDK8 module can inhibit transcription by phosphorylating the 
C-terminal domain of the Pol II subunit before the formation of the preinitiation complex, 
hence disrupting Mediator-Pol II interaction (Hengartner et al., 1998). Furthermore, the 
module seems to be necessary for transcriptional activation of various networks, including 
for example p53 (Donner et al., 2007), serum response (Donner et al., 2010), and HIF1A 
networks (Galbraith et al., 2013). On the other hand, the CDK8 module may also function 
independently of Mediator (Knuesel et al., 2009b). MED12 plays a crucial part in the 
regulation of the CDK8 module since the protein is essential for CDK8 kinase activity 
(Knuesel et al., 2009b). MED12 interacts with several different transcription factors related 
to a variety of developmental pathways, such as the nuclear hormone receptor, Wnt, and 
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Sonic hedgehog signaling pathways (Belakavadi and Fondell, 2006; Kim et al., 2006; Zhou 
et al., 2006; Zhou et al., 2012). MED12 binds, for example, directly to β-catenin, a key 
nuclear effector of the canonical Wnt pathway, and activates the transcription of target 
genes. MED12 can also modulate Sonic hedgehog signaling through a direct interaction with 
Gli3. Furthermore, MED12 contributes to epigenetic silencing of neuronal gene expression 
in non-neuronal cells by linking RE1-silencing transcription factor (REST) with G9a histone 
methyltransferase (Ding et al., 2008). MED12 also interacts directly with several members 
of Sox family, such as Sox9 and Sox10, representing DNA-binding transcription factors 
important for controlling embryonic development (Zhou et al., 2002; Rau et al., 2006; Vogl 
et al., 2013). 
 
In vertebrates, three of the four CDK8 kinase module subunits, MED12, MED13, and 
CDK8, have undergone gene duplications to produce paralogs designated as MED12L, 
MED13L, and CDK19, respectively (Sato et al., 2004; Bourbon, 2008). The role of these 
paralogs on the function of the CDK8 module or Mediator remains unclear, particularly in 
the case of MED12L and MED13L. A recent study indicated that all these paralogs are 
mutually exclusive of each other, albeit not exclusive of the other kinase module members, 
suggesting that CDK8 module may exist in several configurations in the cell (Daniels et al., 
2013). The increased amount of components in the module probably refers to the extended 
number of functions in vertebrates, which could possibly contribute to the gene-specific and 
context-dependent transcription regulation by Mediator.  
 
 
1.3 MED12 hotspot mutations in leiomyomagenesis 
 
Although the cellular origin of uterine leiomyomas remains obscure, identification of 
MED12 hotspot mutations has provided a few insights to the matter. Firstly, the occurrence 
of different MED12 mutations in multiple leiomyomas from the same patient supports the 
notion that the majority of these tumors arise independently (Mäkinen et al., 2011a; 
Markowski et al., 2012; de Graaff et al., 2013). A recent whole-genome sequencing study of 
uterine leiomyomas indicated that a small subset of physically distinct leiomyomas might, 
however, have a common clonal origin (Mehine et al., 2013). The results are consistent with 
Figure 11. Schematic view of CDK8 
module associated with Mediator 
complex. Adapted from Fertility and 
Sterility, 102, Mehine et al., Genomics of 
uterine leiomyomas: insights from high-
throughput sequencing, p.623, Copyright 
Elsevier (2014), with permission from 
Elsevier. 
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some previously published karyotypical findings (Nibert and Heim, 1990; Nilbert et al., 
1990a). Of note, all of the clonally related tumors in the study were MED12 mutation-
negative, which could partially explain the observed clustering of tumors lacking MED12 
mutations in a subset of patients in our original exome sequencing study. Secondly, 
stem/progenitor cells from uterine leiomyoma tissue appear to carry MED12 mutations, 
while no mutations are present in the adjacent myometrium or myometrial stem/progenitor 
cells (Ono et al., 2012). These data suggest that a MED12 mutation may lead to tumorigenic 
transformation in a cell already part of a leiomyoma cell lineage. On the other hand, another 
study did identify MED12 mutations in the adjacent histologically unremarkable 
myometrium of a uterine leiomyoma, proposing that these mutations occur early in 
pathogenesis (Schwetye et al., 2014). Further work is necessary to elucidate the role of 
MED12 as a potential initiator of leiomyomagenesis. 
  
Based on our pathway enrichment analysis of eight MED12 mutation-positive uterine 
leiomyomas and their respective normal myometrium tissue samples, three significantly 
altered pathways emerged, including the Wnt signaling pathway. Since then, a few studies 
have examined the potential role of this pathway in the development of leiomyomas. MED12 
mutation-positive leiomyomas appear to show clear upregulation of WNT4, a member of the 
Wnt signaling pathway, which regulates the formation of the Müllerian ducts, the structures 
that give rise to the uterus, fallopian tubes, cervix, and the upper part of the vagina 
(Markowski et al., 2012). Because estrogen stimulates Wnt4 expression in several cell types 
(Hou et al., 2004; Miyakoshi et al., 2009), it was hypothesized that MED12 and estrogen 
could cooperate in leiomyomagenesis. At the same time, immunohistochemical stainings of 
β-catenin in uterine leiomyomas have demonstrated that the Wnt signaling pathway is not 
constitutively active in tumors with MED12 mutations (Perot et al., 2012; de Graaff et al., 
2013). Nuclear staining of β-catenin, a strong indicator of the activated canonical Wnt 
pathway, was either not present at all or present in approximately half of the mutated tumors, 
depending on the study. Although these results suggest that MED12 mutations probably do 
not generally affect tumorigenesis through the Wnt signaling pathway, activation of the 
pathway may occasionally play a part in a subset of MED12 mutation-positive tumors. It is 
noteworthy that the original pathway enrichment analysis included only eight uterine 
leiomyoma-myometrium pairs, thus the results should be verified with a larger sample series 
in the future. 
 
Recently, functional analyses have indicated that MED12 exon 2 mutations uncouple Cyclin 
C-CDK8/19 from the core Mediator, resulting in diminished CDK8 kinase activity (Turunen 
et al., 2014). At first, affinity-purification mass spectrometry revealed a specific decrease in 
the association of Cyclin C, CDK8, and CDK19 with mutant MED12 (G44D) versus wild-
type MED12. Immunoprecipitation-western blot confirmed the finding and extended the 
results to apply to other MED12 exon 2 mutations, including L36R, Q43P, and G44S. 
Mapping of the Cyclin C-binding domain on MED12 to the first 100 amino acids of the 
protein, a region largely encoded by exons 1 and 2, suggested that MED12 mutations disrupt 
the binding interface between MED12 and Cyclin C. Through this direct binding, MED12 
seems to activate the cyclin-dependent CDK8 kinase activity. Subsequently, uterine 
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leiomyoma-linked MED12 exon 1 mutations have been shown to share a similar molecular 
basis for their tumorigenic role as exon 2 mutations (Kämpjärvi et al., 2014). Overall, these 
findings have implicated aberrant CDK8/19 activity to the genesis of uterine leiomyomas 
and elucidated molecular interactions underlying Mediator kinase activity. Further analyses 
are necessary, however, to assess the next downstream targets of MED12 in 
leiomyomagenesis. 
 
Defects in other components of the CDK8 module, including CDK8/19, Cyclin C, MED13, 
and MED13L, have been implicated in various human tumor types. Especially, the 
dysregulation of CDK8 and CCNC is frequently associated with numerous cancers (Schiano 
et al., 2014). Mutation screening of CDK8/19, CCNC, and MED13 in 70 MED12 mutation-
negative uterine leiomyomas did not identify somatic coding region mutations in these 
genes, suggesting that mutations in these components of CDK8 module do not principally 
contribute to the development of uterine leiomyomas (Mäkinen et al., 2014). These results 
highlight the specificity of MED12 hotspot mutations and their functional effects. 
 
1.4 MED12 mutations in other human tumor types 
 
1.4.1 MED12 hotspot mutations 
 
Ever since the identification of MED12 exon 2 mutations in uterine leiomyomas, numerous 
studies have examined the role of these mutations in other human tumor types, both benign 
and malignant. Uterine leiomyosarcomas, the malignant counterparts of uterine leiomyomas, 
for example, have been of particular interest. Uterine leiomyosarcomas represent extremely 
rare, clinically aggressive tumors with a poor 5-year survival and high recurrence rate (Major 
et al., 1993; Mayerhofer et al., 1999; Giuntoli et al., 2003; Dinh et al., 2004). These tumors 
are traditionally thought to arise de novo; however, according to the literature, some 
leiomyosarcomas may originate from a leiomyoma precursor (Lee et al., 1994; Mittal and 
Joutovsky, 2007; Mittal et al., 2009; Yanai et al., 2010). The discovery of recurrent MED12 
mutations in uterine leiomyosarcomas indicated that occasionally leiomyosarcomas could 
arise from MED12-mutated leiomyomas (Je et al., 2012; Kämpjärvi et al., 2012; Markowski 
et al., 2012; Perot et al., 2012; de Graaff et al., 2013; Matsubara et al., 2013; Ravegnini et 
al., 2013; Bertsch et al., 2014). Furthermore, two MED12 mutation-positive uterine 
leiomyosarcomas displayed identical MED12 mutations with their associated benign 
components (Matsubara et al., 2013). On the other hand, MED12 mutations may give 
leiomyosarcomas a growth advantage. The overall mutation frequencies have proven to be, 
however, much lower than in uterine leiomyomas, only reaching up to 30%, suggesting that 
the majority of leiomyosarcomas and leiomyomas probably develop through different 
genetic pathways. Of note, smooth muscle tumors with uncertain malignant potential 
(STUMP), a rare heterogeneous group of tumors histopatologically imposible to diagnose as 
benign or malignant, also harbor MED12 mutations at a low frequency (11%) (Perot et al., 
2012). All in all, leiomyoma-linked MED12 exon 2 mutations are not restricted to benign 
tumors. 
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Rarely, MED12 exon 2 mutations occur also in leiomyomas outside the uterus, but whether 
these tumors actually have a uterine origin is unclear (de Graaff et al., 2013; Markowski et 
al., 2013; Ravegnini et al., 2013). Only one single extrauterine leiomyosarcoma has 
displayed a MED12 mutation: a soft tissue mass in the thigh with femoral involvement 
(Schwetye et al., 2014). In addition to smooth muscle tumors, MED12 exon 2 mutations 
have been reported at very low frequencies in colon carcinomas (0.3-0.5%) (Je et al., 2012; 
Kämpjärvi et al., 2012) and in single cases of endometrial polyps (Markowski et al., 2012), 
basal triple-negative breast carcinomas (Shah et al., 2012), and chronic lymphatic leukemias 
(CLL) (Schuh et al., 2012). To date, no MED12 exon 1 mutations have been reported in 
other human tumors (Kämpjärvi et al., 2014). 
 
Until lately, leiomyoma-linked MED12 hotspot mutations have appeared to be uterus-
specific and rare in other human tumors. Recent identification of MED12 exon 2 mutations 
in 59% of breast fibroadenomas with the observed mutation spectrum nearly identical to that 
of uterine leiomyomas strongly suggests that the tumors share a common genetic basis (Lim 
et al., 2014). Breast fibroadenomas represent common benign tumors with a different 
anatomical location and tissue type compared to uterine leiomyomas. Both tumor types, 
however, are female-specific and hormone-dependent, localizing in key target tissues of 
estrogen (Zhu and Conney, 1998). This proposes that MED12 exon 2 mutations may relate 
to hormonal expression. Depletion of MED12 has been previously shown to impair ERα-
regulated transcription (Prenzel et al., 2012). In the future, it would be interesting to see if 
the loss of CDK8 kinase activity influences the transcription of genes involved in estrogen 
metabolism. Moreover, since the N-terminal MED12 mutations are present only in a few 
tissue types, their tumorigenic effect likely has something to do with gene-specific, rather 
than global, transcription. 
 
1.4.2 Other MED12 mutations 
 
In addition to leiomyoma-linked MED12 hotspot mutations, mutations in other parts of 
MED12 have also been associated with human diseases. Exome sequencing analyses of two 
hormone-related cancers, prostate and adrenocortical carcinomas, have identified somatic 
MED12 mutations at low frequency in the tumors (Barbieri et al., 2012; Assie et al., 2014). 
Despite the low frequency, MED12 is at the moment one of the most recurrently mutated 
genes in prostate carcinomas. Nevertheless, the location and type of the mutations suggest 
that the molecular mechanisms underlying these tumors most likely differ from that of 
uterine leiomyomas and breast fibroadenomas. For example, single mutations observed in 
adrenocortical carcinomas affect the β-catenin binding site at the C-terminal region of 
MED12. 
 
1.5 MED12 germline mutations 
 
Various MED12 germline mutations affecting the LS domain of the protein (Figure 10) are 
responsible for three different forms of X-linked mental retardation syndromes: Opitz-
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Kaveggia syndrome (MIM 305450) (Risheg et al., 2007; Rump et al., 2011), Lujan-Fryns 
syndrome (MIM 309520) (Schwartz et al., 2007), and Ohdo syndrome (Maat-Klevit-Brunner 
type) (Vulto-van Silfhout et al., 2013). None of these syndromes are associated with tumor 
predisposition. Once again, the molecular mechanisms underlying the syndromes are likely 
to be different. The current hypothesis suggests that MED12 germline mutations may impair 
the recruitment of Mediator to RE1-silencing elements disrupting REST-imposed epigenetic 
restrictions on neuronal gene expression (Ding et al., 2008; Vulto-van Silfhout et al., 2013). 
 
2. Molecular classification of uterine leiomyomas 
 
Traditionally karyotypic chromosome abnormalities, such as deletions of 7q, trisomy 12, or 
rearrangements of 12q14-15 or 6p21, have enabled classification of uterine leiomyomas into 
subgroups. Since the identification of MED12 exon 2 mutations, the coincidence of the 
mutations and chromosomal abnormalities has been under study (Markowski et al., 2012; 
McGuire et al., 2012; Bertsch et al., 2014). The clear majority of MED12 mutations are 
present in leiomyomas with an apparently normal karyotype, whereas rearrangements of 
12q14-15 occur exclusively in leiomyomas lacking MED12 mutations. These findings 
strongly suggest that MED12 mutations and HMGA2 overexpression due to chromosomal 
rearrangements are independent genetic events, which represent two alternative pathways in 
the tumorigenesis of uterine leiomyomas (Figure 12). Further evidence for mutual 
exclusivity comes from gene expression profiling analyses. While our preliminary gene 
expression analysis of ten uterine leiomyoma-myometrium pairs showed separate clustering 
of MED12 mutation-positive leiomyomas from MED12 mutation-negative tumors and the 
respective myometrial tissue samples, the small number of specimens caused speculation 
that the observed correlation could result from changes other than these mutations. Since 
then, a hierachical clustering analysis of 38 uterine leiomyomas has confirmed the unique 
gene expression profile of MED12 mutation-positive leiomyomas, which evidently differs 
from that of HMGA2-overexpressed tumors (Hodge et al., 2012; Mehine et al., 2013). Taken 
together, MED12 and HMGA2 pathways might account for as much as 80-90% of uterine 
leiomyomas. Of note, RAD51B, the candidate translocation partner for HMGA2, has 
appeared as the most significantly upregulated gene among MED12 exon 1 and 2 mutation-
positive leiomyomas, further suggesting a role for the gene in leiomyomagenesis (Mehine et 
al., 2013; Kämpjärvi et al., 2014).  
 
In contrast to HMGA2, rearrangements of 6p21 affecting HMGA1 can co-exist with MED12 
mutations in the same tumor, providing novel information on their possible role as secondary 
events in respect to MED12 in uterine leiomyomas (Markowski et al., 2012). At the same 
time, chromosome 7q deletions not only co-occur with MED12 mutations, but also with 
HMGA2 rearrangements, confirming earlier observations suggesting that these chromosomal 
changes represent secondary alterations in the development of leiomyomas (Mashal et al., 
1994; Xing et al., 1997). Moreover, one leiomyoma with trisomy 12 has also been shown to 
display a MED12 mutation (Markowski et al., 2012). Recent whole-genome sequencing 
analysis of uterine leiomyomas discovered that a subset of tumors harbor interconnected 
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complex chromosomal rearrangements resembling chromotripsis; a phenomenon in which 
one or a few chromosomes shatter into pieces and randomly assemble back together in a 
single event (Stephens et al., 2011; Mehine et al., 2013). Chromotripsis has previously been 
associated with malignant neoplasms, poor prognosis, and TP53 mutations (Forment et al., 
2012). Thus, this finding suggests that the phenomenon is not only limited to malignant 
tumors, but can also exist in benign lesions lacking TP53 mutations. The majority of the 
leiomyomas harboring complex chromosomal rearrangements were MED12 mutation-
negative showing either HMGA1 or HMGA2 overexpression. These data together with 
exome sequencing data indicate that MED12 mutation-positive leiomyomas are stable at the 
nucleotide level and carry relatively few chromosomal aberrations. This suggests that the 
mutations alone may be vital for leiomyomagenesis. Curiously, a similar pattern has been 
seen previously in melanocytic nevi, which harbor specific missence mutations in BRAF; 
critical in the initiation of melanocytic neoplasia, but alone insufficient for malignant 
progression (Pollock et al., 2003). 
 
  
 
 
 
 
Figure 12. Schematics of the various potential independent pathways in the tumorigenesis of uterine 
leiomyomas. Secondary changes are likely to confer additional growth advantage to a neoplastic cell during 
tumor development. 
FH-deficient uterine leiomyomas, in other words tumors showing biallelic FH inactivation, 
harbor a distinct gene expression profile from MED12 mutation-positive and HMGA2 
overexpressed tumors, providing further evidence for the mutual exclusivity of biallelic FH 
inactivation and MED12 mutations (Vanharanta et al., 2006; Mehine et al., 2013). 
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Furthermore, another distinct gene expression pattern consisting of leiomyomas with 
COL4A5-COL4A6 alterations has emerged (Mehine et al., 2013). So far, these alterations 
have not co-existed with MED12 mutations, HMGA2 rearrangements, or biallelic FH 
inactivation, but data are insufficient to draw conlusions. Alterations in COL4A5-COL4A6 
have previously been observed in the germline of patients with Alport syndrome and diffuse 
leiomyomatosis (Garcia-Torres et al., 2000; Thielen et al., 2003). Both FH-deficient uterine 
leiomyomas and leiomyomas with COL4A5-COL4A6 alterations may represent two rare 
independent subgroups of uterine leiomyomas, leaving only a small portion of the tumors 
genetically unexplained (Figure 12). Overall, these data are in line with previous notions that 
diverse mechanisms may contribute to the growth and development of uterine leiomyomas. 
Further work is necessary to unravel the precise molecular mechanisms underlying each 
tumor subgroup. In conclusion, NGS technologies have provided several new insights into 
the tumorigenesis of uterine leiomyomas and substantially advanced the molecular 
classification of the tumors. 
 
3. Clinical relevance 
 
Most studies on uterine leiomyomas rely on tissue samples removed at surgery from women 
with symptomatic lesions, who have not benefited from previous non-surgical treatments. 
The samples may also be biased towards larger tumor size, which can be easier to collect for 
research purposes. Thus, the possibility exists that the research samples do not completely 
represent leiomyomas in general. At the same time, they do reflect those leiomyomas which 
have proven to be clinically relevant. 
 
In addition to tumor size, the correlation between MED12 mutation status and several other 
clinical variables has been assessed. Patients with MED12 mutation-positive tumors seem to 
have more lesions in their uteri than patients with tumors lacking MED12 mutations 
(McGuire et al., 2012; Heinonen et al., 2014). The smaller size of MED12 mutation-positive 
tumors may potentially result from the multiplicity of the tumors, or alternatively the tumors 
may possess a different growth pattern. Although leiomyomas lacking MED12 mutations, 
such as those harboring HMGA2 rearrangements, can on behalf of their larger size cause 
notable symptoms, the smaller MED12 mutation-positive lesions are likely to result in a 
similar outcome due to their numbers. Higher body mass index is a clinical variable that may 
slightly increase the chances to develop MED12 mutation-positive leiomyomas (Heinonen et 
al., 2014). Obesity is a known risk factor for uterine leiomyomas, increasing the amount of 
biologically available estrogen in the tissue, which potentially can affect tumor development 
and growth. Other clinical factors related to hormone metabolism, such as parity and 
menarche, however, exhibited no correlation with MED12 mutation status. Several studies 
have reported no correlation either between the mutation status and patient’s age at 
hysterectomy (Je et al., 2012; McGuire et al., 2012; de Graaff et al., 2013; Bertsch et al., 
2014; Heinonen et al., 2014). In the future, a larger sample series with comprehensive 
clinical data is essential to have a better understanding of the correlations between distinct 
uterine leiomyoma subgroups and clinical factors. 
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Identification of extremely common somatic MED12 hotspot mutations has improved our 
knowledge regarding the pathogenesis of uterine leiomyomas, but at the same time, provided 
an attractive as well as specific target for drug development. It is still, however, early days to 
design targeted therapies and further analyses are necessary to clarify the molecular biology 
underlying MED12-related leiomyomagenesis. Instead of MED12 itself, the MED12/Cyclin 
C interface or other potential downstream components of the pathway could also serve as 
compelling drug targets. It is worth noticing that uterine leiomyomas do not represent a 
uniform, but rather heterogeneous, group of tumors not responding only to one kind of 
therapy. The majority of leiomyomas display MED12 mutations or HMGA2 overexpression 
making these two independent tumorigenic pathways currently the most promising targets 
for therapy. An accurate molecular classification of the tumors is a requirement for improved 
management and personalized medical treatments in the future. 
 
In addition to uterine leiomyomas, identification of MED12 mutations has provided new 
perspectives on the biology of uterine leiomyosarcomas, representing one of the few 
recurrent genetic alterations observed in both benign and malignant counterparts. In most 
cases, the clinical behavior of uterine smooth muscle tumors can be reliably predicted based 
on their gross and microscopical appearances. Diagnostic challenges emerge still in daily 
pathological practice in distinguishing uterine leiomyosarcomas from benign leiomyoma 
variants, which mimic malignancy. Any new knowledge of the mechanisms underlying the 
potential progression to malignancy is essential, because the diagnosis of uterine 
leiomyosarcomas is often unexpected and postoperative. The low frequency of MED12 
mutations in both leiomyosarcomas and histopathological leiomyoma variants suggests that 
most of these tumors develop likely through distinct genetic mechanisms. In the future, it 
would be interesting to further study the possibility that some conventional leiomyomas or 
histopathological leiomyoma variants could act as precursors for leiomyosarcomas.  
 
NGS technologies have considerably improved our understanding of the somatic genomic 
lanscapes of different human tumor types over a very short period of time, providing 
information on, for example, novel mutational processes and new disease genes, as in uterine 
leiomyomas. At the same time, high-throughput sequencing of tumors has led to unexpected 
germline findings, unrelated to the research in question. One of the continuing bioethical 
debates in genomics research is how much information on these incidental findings should 
be passed to the patient. Occasionally, these unexpected findings may offer the patient 
clinically relevant health-related information. In those cases, if the patient has wished to 
receive the research results based on signed informed consent, he can be informed and 
guided to appropriate counseling and formal genetic testing. It is important, however, that 
the patient has been appropriately instructed prior to the next-generation sequencing effort 
that unexpected genetic information, which has nothing to do with the ongoing research, can 
be identified. It is also good to bear in mind that patients represent the general population, 
varying in education and genetic expertise. 
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
This thesis work describes a prominent new finding in the genetics of uterine leiomyomas: 
the identification of recurrent somatic MED12 exon 2 mutations in up to 70% of the tumors. 
Concurrently, the thesis work implicates MED12 in human tumorigenesis for the first time. 
The finding has since been validated in a variety of ethnic groups worldwide indicating a 
major role for these mutations in leiomyomagenesis. All in all, the high MED12 mutation 
frequency, clustering of the mutations into a definite evolutionarily conserved region of the 
protein, and mutation pattern establish MED12 as a novel candidate driver gene, which is 
likely to function as an oncogene. 
 
MED12 is part of a multiprotein Mediator complex, which is necessary for regulating the 
transcription of Pol II-dependent genes. Functional studies of MED12 mutations have so far 
associated aberrant CDK8/19 kinase activity with the genesis of uterine leiomyomas. The 
disruption of the MED12-Cyclin C binding interface, required for the activation of Cyclin C-
dependent CDK8/19 kinase activity, detaches the Cyclin C-CDK8/19 from the core 
Mediator. Further analyses are essential to assess whether uncoupling of Cyclin C-CDK8/19, 
for example, enables these proteins to carry out their possible independent functions or 
activates/represses the function of the core Mediator. Pathway enrichment analysis with a 
large sample series could potentially produce a more accurate view of signaling and 
metabolic pathways, or molecular networks involved in leiomyomagenesis and help to 
predict their downstream effects. Interestingly, the existence of MED12 exon 2 mutations in 
the majority of breast fibroadenomas suggests that the mutations may play a part in 
hormonal expression. One hypothesis could be that the loss of CDK8/19 kinase activity 
affects the transcription of genes involved in estrogen metabolism. Other benign hormone-
dependent tumors in females naturally represent prospective research subjects to further 
examine the plausible link between MED12 mutations and hormones. It is worth noting that 
the discovery of MED12 exon 2 mutations has not only provided new insights into 
leiomyomagenesis, but also elucidated molecular interactions important for Mediator kinase 
activity. Leiomyoma-linked mutations have also given new tools for researchers to study the 
function of MED12 further. For example, future functional analyses on the N-terminal 
region of the protein could clarify molecular mechanisms underlying CDK8-driven cancers. 
 
During the last few years the use of NGS technologies has substantially improved our 
knowledge of the molecular genetic background of uterine leiomyomas. NGS has led to 
several major findings in these tumors, such as the identification of novel driver genes and 
complex chromosomal rearrangements resembling chromotripsis. These discoveries together 
with previous cytogenetic data have considerably advanced the molecular classification of 
leiomyomas. Although most driver genes in the tumors may have been recognized, other less 
frequent genomic changes affecting tumor initiation and progression are likely to exist. In 
forthcoming studies, it would be important to examine if certain clinical variables are 
associated with certain molecular genetic characteristics in leiomyomas. Consequently, the 
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stratification of uterine leiomyomas into clinically relevant subgroups enables improved 
management and can lead to more personalized medical treatments. 
 
In contrast to conventional leiomyomas, histopathological leiomyoma variants, uterine 
leiomyomas from HLRCC-patients, and malignant uterine leiomyosarcomas harbor 
significantly fewer MED12 mutations, suggesting that they may develop primarily through 
distinct molecular mechanisms. In the case of tumors from HLRCC-patients, biallelic FH 
inactivation, present in the majority of tumors, seems to be mutually exclusive with MED12 
mutations, explaining the result. Further genetic analyses on histopathological leiomyoma 
variants and uterine leiomyosarcomas, however, could possibly reveal additional factors 
involved in the tumorigenesis of these lesions. In the future, it would also be interesting to 
study the possible malignant transformation of conventional leiomyomas or 
histopathological leiomyoma variants. New knowledge of the mechanisms underlying the 
potential progression into malignancy would provide valuable data to the current diagnosis 
of uterine leiomyosarcomas, which is often unexpected and postoperative. 
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